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Abstract 
 
Background: With the development of next-generation sequencing technologies, it is possible to 
identify rare genetic variants that influence the risk of complex disorders. To date, whole exome 
sequencing (WES) strategies have shown that specific clusters of damaging rare variants in the 
TREM2, SORL1 and ABCA7 genes are associated with an increased risk of developing Alzheimer’s 
Disease (AD), reaching odds ratios comparable with the APOE-ε4 allele, the main common AD 
genetic risk factor. Here, we set out to identify additional AD-associated genes by an exome-wide 
investigation of the burden of rare damaging variants in the genomes of AD cases and cognitively 
healthy controls. 
Method: We integrated the data from 25,982 samples from the European ADES consortium and 
the American ADSP consortium. We developed new techniques to homogenize and analyze these 
data. Carriers of pathogenic variants in genes associated with Mendelian inheritance of dementia 
were excluded. After quality control, we used 12,652 AD cases and 8,693 controls for analysis. 
Genes were analyzed using a burden analysis, including both non-synonymous and loss-of-
function rare variants, the impact of which was prioritized using REVEL. 
Result: We confirmed that carrying rare protein-damaging genetic variants in TREM2, SORL1 or 
ABCA7 is associated with increased AD-risk. Moreover, we found that carrying rare damaging 
variants in the microglial ATP8B4 gene was significantly associated with AD, and we found 
suggestive evidence that rare variants in ADAM10, ABCA1, ORC6, B3GNT4 and SRC genes 
associated with increased AD risk. High-impact variants in these genes were mostly extremely 
rare and enriched in AD patients with earlier ages at onset. Additionally, we identified two 
suggestive protective associations in CBX3 and PRSS3. We are currently replicating these 
associations in independent datasets. 
Conclusion: With our newly developed homogenization methods, we identified novel genetic 
determinants of AD which provide further evidence for a pivotal role of APP processing, lipid 
metabolism, and microglia and neuroinflammatory processes in AD pathophysiology. 
 
 
Introduction 
Alzheimer's disease is the leading cause of dementia and its impact will continue to grow due to 
the increase in life expectancy (1) Beyond rare autosomal dominant forms of early onset AD (less 
than 1% of all AD cases), the common complex form of AD has an estimated heritability of ~70% 
(2)  This heritability can be explained by the aggregated effect of many genes associated with AD 
risk. Deciphering this genetic component to the gene or even to the variant level offers a unique 
window of opportunity to (i) better define the aetiology underlying the disease; and (ii) to 
develop polygenic risk scores that may predict who will develop AD before clinical symptoms 
occur. Comprehensive knowledge of disease etiology is thus essential for the future development 
of treatment strategies, which will likely be most effective when administered to those with 
relevant genetic risk, before irreparable damage to brain cells has occurred. 
With such ambitious objectives, important efforts have been made to characterize the 
comprehensive genetic landscape of AD. With the advent of genome wide association studies 
(GWAS) based on DNA chips, numerous common genetic risk factors/loci have been associated 
with the risk of AD over the 10 last years (3, 4). However, our knowledge of the genetic 
component underlying AD is far from complete. While further efforts are underway to capture 
additional genetic information using GWASs, this approach is not really designed to efficiently 
capture the effect of rare (and even more singleton) variants on disease risk. However, rare 
variants are expected to explain at least part of the missing heritability of most complex diseases, 
including AD. 
With the development of the next-generation sequencing technologies, it is possible to identify 
rare variants in genetic sequences. To date, whole exome sequencing (WES) strategies have 
shown that rare missense or loss-of-function variants in the TREM2, SORL1 and ABCA7 genes are 
associated with an increased risk of developing AD with a moderate to high effect (5-9). For the 
SORL1 gene, loss of function variants were associated with an increased risk of AD with an odds 
ratio in ranges that were not observed since the identification of the main AD genetic risk factor, 
the common APOE-ε4 allele (9-12). 
The detection of additional AD associated genes by investigating the differential burden of rare 
damaging variants between AD cases and controls requires very large sample sizes. Variants are 
often very rare such that many cases and controls are necessary to collect enough evidence for 
a statistically significant association. In addition, beyond issues of statistical power, WES analyses 
need to take into account common technical biases leading to strong batch effects that can have 
important impacts on the generated results with a risk to generate false positives or negatives. 
Furthermore, all genes have unique features, both functionally and genetically, and this is 
reflected by the diverse characteristics of variants that drive their association with AD. Using 
WES, unique variants may be observed in very few or only single carriers which requires alternate 
interpretation strategies compared to the classical GWAS analyses in which all measured variants 
are common. For these reasons, genome-wide comparisons of rare variants in AD cases and 
controls have likely not yet led to the identification of novel AD-associated genes beyond SORL1, 
ABCA7 and TREM2,(12) 
Here, to identify an association between the burden of rare coding variants at the gene level, we 
developed novel analysis methods to study the largest WES dataset available worldwide 
encompassing 21,345 samples (12,652 AD cases and 8,693 controls). This unique effort led to the 
identification of 11 genes associated with AD-risk, of which rare variants in eight genes were not 
previously significantly associated with AD genetic risk. Per gene, we report the effect sizes of the 
variant burden after a final refinement analysis that takes into account that a uniform exome-
wide analysis does not comply with gene-specific idiosyncrasies.  
 Methods 
Sample 
We analyzed the exome sequences of 25,982 individuals: sequence data from 15,088 individuals 
was collected as part of the Alzheimer Disease European Sequencing consortium (ADES) and 
sequence data from 11,365 individuals was obtained from the Alzheimer’s Disease Sequencing 
Project (ADSP) (12), see Table S1 for samples contributed per study. The total sample comprised 
14,658 AD cases and 10755 controls (569 were N/A). For sample description, see supplemental 
data. DNA samples were sequenced using a paired-end Illumina platform, whole exome 
sequences (WES) was generated using different exome capture kits (Table S2), a subset of the 
sample was sequenced using whole genome sequencing (WGS) (Figure S1, Table S2).  
 
Data processing, Quality control (QC) and genotype calling 
Raw sequencing data from all studies were collected on a single site and processed relative to 
the GRCh37 reference genome, using a uniform pipeline as described in detail in the 
supplementary methods. On the merged sample, we performed a sample QC (Figure 1a) after 
which 21,345 samples were available for analysis: 12,652 cases (4,060 EOAD, onset ≤ 65 years) 
and 8,693 controls. The variant QC was applied as described in Figure 1b; variant selection and 
annotation was performed as described in Figure 1c: The burden analysis was performed at the 
gene level based on protein-coding Ensembl transcripts with a ‘Gencode basic’ tag. Missense 
variants were annotated using REVEL (Rare Exome Variant Ensemble Learner) (13, 14) and LOF 
variants were annotated using LOFTEE (15). We selected variants that were estimated to have at 
least one carrier, and had a minor allele frequency (MAF) of <1%. We removed variants with 
>20% genotyping missingness or that did not pass a filter for differential missingness between 
the EOAD, LOAD and control groups (genotypes with a read depth <6 are considered missing, see 
supplement).  
 
Gene burden test: Variant impact categories and thresholds 
Variants were divided in four deleteriousness categories: a LOF category, and 3 missense 
categories: REVEL ≥ 75, REVEL 50-75 and REVEL 25-50 (Figure 1c). Based on these, we constructed 
four deleteriousness thresholds in which we incrementally added variants with lower levels of 
variant predicted deleteriousness: first only LOF variants, then LOF variants + variants with a 
REVEL score ≥75, then LOF + REVEL≥50, and last LOF + REVEL≥25. This allows us to concentrate 
on the test which provides maximum evidence for a differential burden-signal. Multiple testing 
correction was performed across all performed tests (up to 4 per gene).  
 
Gene burden test: age-at-onset association 
Based on previous findings in SORL1, TREM2 and ABCA7 (16), we expect an enrichment of high 
impact rare risk variants in early onset cases relative to late onset cases. Therefore, we applied a 
test based on ordinal logistic regression, in which the genetic risk for AD is considered to increase 
in the sample categories: i.e. burdenEOAD > burdenLOAD > burdencontrol. This test is optimally suited 
for picking up differential variant loads between the sample categories, and can also detect 
regular case-control signals for which genetic risk is equally distributed across EOAD and LOAD 
cases (burdenEOAD ~ burdenLOAD > burdencontrol) as well as EOAD-specific signals (burdenEOAD > 
burdenLOAD ~ burdencontrol). We considered an additive model, while correcting for population 
covariates (see supplement). Genes were only tested if the cumulative minor allele count (cMAC) 
of predicted damaging variants was ≥10. Genes were considered suggestively associated with AD 
if the False Discovery Rate (FDR) (Benjamini-Hochberg procedure (17) as <20% (FDR<0.2). Genes 
were considered significantly associated with AD in our discovery sample when the corrected p 
was <0.05 after family-wise correction using the Holm-Bonferoni procedure (18).  
 
Gene burden test: Testing for an age-at-onset or a 
deleteriousness-category effect 
To test whether the burden of damaging variants increased (or decreased for protective variants) 
towards younger patients, an ordinal regression was performed using only cases (no controls). 
Cases were grouped in 4 age-at-onset bins: ≤65, (65-70], (70-80] and >80. A significant effect (FDR 
< 0.05) signaled that there was a difference in enrichment between young and older cases. To 
determine if there was a significant trend in effect sizes between the different deleteriousness 
categories (REVEL 25-50, 50-75, 75-100 and LOF), an ordinal logistic regression test was 
performed with constrained beta’s |𝑏𝑅𝐸𝑉𝐸𝐿 25−50| ≤ |𝑏𝑅𝐸𝑉𝐸𝐿 50−75| ≤ |𝑏𝑅𝐸𝑉𝐸𝐿 75−100| ≤ |𝑏𝐿𝑂𝐹|, 
and compared to a H0-model with a single beta (see supplement).  
Carrier frequency and odds ratios 
A carrier of a set of variants was defined as a sample for which the summed dosage of those 
variants was ≥0.5. Carrier frequencies (CFs) were determined as #carriers / #samples. Effect sizes 
(odds ratios, ORs) of the ordinal logistic regression can be interpreted as weighted averages of 
the OR of being an AD case versus control, and the OR of being an early-onset AD case or not. 
Ordinal odds ratios were calculated for each test, as well as separately for the 4 variant categories 
REVEL 25-50, 50-75, 75-100 and LOF. Next to ordinal ORs, we estimated ‘standard’ ORs. This was 
done across all samples (case/control), as well as per age category (EOAD versus controls and 
LOAD versus controls), as well as for smaller age-at-onset categories: ≤65 (EOAD), (65-70], (70-
80] and >80 using multinomial logistic regression, while correcting for 6 PCA covariates.  
 
Sensitivity analysis 
A sensitivity analysis was performed to determine if effects were potentially due to age 
differences between cases and controls. We constructed an age-matched sample, by dividing 
samples in strata based on age/age-at-onset, with each stratum covering 2.5 years. Case/control 
ratios in all strata were kept between 0.1 and 10 by down sampling respectively controls or cases. 
Subsequently, samples were weighted using the propensity weighting within strata method 
proposed by Posner and Ash (19). Finally, a case-control logistic regression was performed both 
on the unweighted and weighted case-control labels, and estimated odds ratios and confidence 
intervals were compared.  
 
Variant-specific analysis 
We performed a variant-specific analysis of the genes considered as significantly or suggestively 
associated with AD, to detect gene-specific idiosyncrasies not covered by our uniform exome-
wide analysis. We checked for outlier variants among those that were included in the burden 
test, determining which ones had a significantly lower or opposite effect size (fisher exact test) 
compared to other included variants of the same category (missense or LOF). Furthermore, we 
determined which missense or potential LOF variants did associate with AD (logistic regression 
test, at least 15 carriers), irrespective of REVEL/LOFTEE or MAF thresholds. We performed 
corrections for multiple testing per gene using FDR, reporting only variants with a threshold of 
FDR < 0.2 (Table S3). We manually removed and added these variants to the burden tests, in 
order to calculate, next to standard odds ratios, also refined odds ratios. 
Results 
 
Sample description: 
After sample QC (Figure 1a), 21,345 participants were included in the main analysis (12,652 
cases; 8,693 controls) (Table 1). AD cases were separated in EOAD cases with age at onset ≤ 65 
(n=4,060) and LOAD cases (N=8,592). All demographic data are available in Table S1. As expected, 
cases were more likely to carry at least one APOE ε4 allele: the fraction of homozygous APOE ε4 
carriers was 6.6% of the cases vs. 0.9% of the controls; fraction of heterozygous APOE ε4 carriers 
was 40.6% of the cases vs 18.4% of the controls (Table 1).  
 
Burden tests using different deleteriousness thresholds 
We detected a total of 13,522,252 variants in these individuals, and 7,674,898 variants passed 
quality control (Figure 1b). These variants were annotated according to four predicted 
deleteriousness categories based on LOFTEE score for LOF variants and the REVEL prediction 
score for missense variants. Finally, we selected 407,032 coding missense and loss of function 
(LOF) variants with MAF <1% based on criteria as described in the methods (Figure 1c). We used 
four deleteriousness thresholds by incrementally including variants with on lower levels of 
variant predicted deleteriousness: respectively LOF (n=56,565), LOF + REVEL≥75 (n=109,576), LOF 
+ REVEL≥50 (n=208,720), and LOF + REVEL≥25 (n=407,032). 
 
Among the 19,822 autosomal protein-coding genes considered in our annotation, we tested 
13,299 genes with at least 10 minor alleles (cumulative minor allele count or cMAC ≥ 10) 
appertaining to the LOF+REVEL≥25 variant threshold. For the remaining genes, the burden of 
variants per gene was considered too low (cMAC<10) to infer any dependable signal. 
For the LOF+REVEL≥50, the LOF+REVEL≥75 and the LOF-only thresholds, respectively 9,255, 5,781 
and 3,233 genes reached the minimum of having at least cMAC ≥10 to allow testing (Figure 2). In 
sum, 31,568 tests were performed across 13,299 genes. Of note, since we tested each gene for 
having a differential variant burden in cases and controls for different deleteriousness thresholds, 
a single gene could theoretically be identified multiple times in the burden test.  
 
Identification of genes for which rare variant-burden associates 
with AD risk 
We performed 31,568 tests in our analysis, and the genetic inflation of our analysis model was 
𝝀=1.038 (Figure 3). Of all tests, 19 tests passed the FDR<0.2 threshold for having a suggestive 
differential variant burden in AD cases and controls (Table 2, Figure 3). These tests covered 11 
genes (in order of significance): SORL1, TREM2, ABCA7, ATP8B4, ADAM10, ABCA1, ORC6, CBX3, 
PRSS3, B3GNT4 and SRC. Of these, 6 tests (covering 4 genes) were significant when using a more 
conservative family-wise error rate correction for multiple testing (Holm-Bonferoni corrected 
p<0.05): SORL1, TREM2, ABCA7, and ATP8B4. 
The predicted deleteriousness and the number of identified rare variants varied per gene. We 
aimed to accommodate for this variability by using different deleteriousness predictions 
thresholds. Tests using the LOF+REVEL≥25 threshold provided the most evidence for an 
association between variant-burden and AD risk (i.e. lowest p value) for the TREM2, ABCA7, 
ATP8B4, ORC6, CBX3, PRSS3, B3GNT4 genes. Tests using the LOF+REVEL≥50 threshold provided 
the most evidence for SORL1, ABCA1 and SRC, and testing using the LOF+REVEL≥75 threshold 
provided the most evidence for an association for the ADAM10 gene (Table 2, Figure 3). The 
SORL1, ABCA7, ATP8B4, ADAM10, and ABCA1 genes were identified using multiple thresholds 
(light grey gene names in Figure 3). Most genes were associated with an increased burden in 
cases, but at the FDR<0.2 significance level we identified CBX3 and PRSS3 which exhibited a lower 
burden of LOF+REVEL≥25 variants in cases than in controls, indicating potential protective 
association (Table 2). 
 
Dependence of effect sizes on variant deleteriousness category 
Next, we investigated the effect on AD risk for variants from the four predicted variant 
deleteriousness categories. In our dataset all genes (except CBX3) included LOF variants. For 7 
genes, we identified at least 3 carriers with LOF variants (SORL1, TREM2, ABCA7, ATP8B4, 
ADAM10, ABCA1, ORC6). For 6 of these 7 genes, we observed that the LOF variant category had 
a higher ordinal OR point-estimate than the (missense) variant categories (p=0.06, binomial test) 
(Figure 4). Finally, when tested whether variant impact was ordered according to predicted 
deleteriousness: LOF ≥ REVEL 75-100 ≥ REVEL 50-75 ≥ REVEL 25-50 using a trend test (see 
methods), this test was significant (FDR<0.05) for SORL1, ADAM10, and ABCA1.  
Relation between variant-burden and age at onset 
Subsequently, we investigated the relationship between age and variant-burden by testing if 
variant-burden in AD patients decreased with the age at onset categories ≤65 (EOAD), 65-70, 70-
80 and >80 (Figure 5). The median age at onset in the complete dataset was 73. For most of the 
identified genes, the burden of damaging variants was highest in younger cases, and decreased 
with increasing age at onset. The median age at onset of case carriers, was lowest in ORC6 (60y), 
followed by ADAM10 (62y), SRC (64y), B3GNT4 (66y), SORL1 (67y), ABCA1 (70y), TREM2 (70y), 
ABCA7 (70y) and was the highest in ATP8B4 (72y). Notably, while the median age at onset of 
missense variants in SORL1 was 68, it was lower for LOF variant carriers (60). In the ATP8B4, CBX3, 
and PRSS3 genes we observed no relationship between the variant burden and age at onset. Note 
that the variants in the latter two genes were associated with a protective effect, and therefore 
most carriers are controls.  
 
Carrier or variant frequency 
In line with the above, the fraction of variant carriers generally decreased with increasing age 
(Figure 5). However, a considerable fraction of older AD patients carries variants in the SORL1, 
TREM2, ABCA7, ATP8B4 and ABCA1 genes, suggesting that variants in these genes also contribute 
to an increased risk of late-onset AD. Of note, there were only a few carriers of damaging variants 
in the ADAM10, ORC6, B3GNT4 and SRC genes (respectively 13, 16, 29 and 27 carriers), such that 
impairment of these genes is likely to contribute to AD in only a few patients.  
A relatively large fraction of variants from the most significant variant threshold per gene were 
singletons, i.e. variants that were carried by only a single individual in our dataset (Figure 6a). 
There were 126 carriers of a singleton variant in SORL1 (43%), 9 in ADAM10 (69%), 105 in ABCA1 
(48%), 14 in ORC6 (88%), 17 in B3GNT4 (59%) and 10 in SRC (37%). However, the AD-association 
of the TREM2, ABCA7 and ATP8B4 genes was carried by more common variants: singletons were 
identified in only 8 carriers (3%), 167 carriers (13%) and 45 carriers (6%). Finally, in the protective 
genes we also found relatively low numbers of singletons: 0 in CBX3 (0%) as the association signal 
was driven by a single recurrent variant and 14 in PRSS3 (13%), indicating that their protective 
signal was effectuated by more common (but still rare) variants. We further tested if the effect 
size trended to be higher for the rarer variants: a significant trend (FDR<0.05) was observed for 
SORL1 (p≤0.00004) and ABCA1 (p≤0.00004), and a suggestive trend in TREM2 (p=0.04) (Figure 6). 
 
Age-matched analysis 
To investigate whether the observed variant burden-effects were AD-specific, or whether they 
could also be explained by other age-related diseases, we performed a sensitivity analysis with 
strict age-matching. There was a strong agreement between the effect sizes when comparing 
age-matched case-control analysis and the case-control analysis unselected for age (Figure S3). 
The age-matched analysis supported for each gene a role in AD, but based on the confidence 
intervals for the effect of the SRC gene, we cannot exclude the possibility that observed effects 
might also be attributable to a non-AD age-related disease. We observed a slight reduction in the 
effect size in the age-matched analysis, as observed for SORL1 and TREM2. This was according to 
expectations, as mortality due to AD causes an additional age-related effect between young cases 
and old controls, which is removed by the age-matching.  
 
APOE-ε4 sensitivity analysis 
We did not correct our analysis for the common APOE genotype because this is not a confounder 
for the identification of a differential burden of rare variants between cases and controls. To 
investigate the validity of this assumption, we performed a sensitivity analysis in which we 
compared analysis corrected and uncorrected for carriership of the APOE-ε4 allele, which did not 
change our results (Figure S2).  
 
Gene specific analysis 
For our genome wide burden analysis variant selection criteria and thresholds were uniformly 
applied to all variants in each gene. Therefore, it was necessary to refine burden effects by 
correcting for variants with divergent effects compared to the variants in the burden (see 
Methods and Table S3). Gene-specific analyses are described for each gene in the Supplementary 
Material. This led to a refinement of the associations of SORL1, TREM2, ABCA7, and ABCA1 (Table 
1, Figure 7).  
 
Carriers of multiple variants 
We finally measured the presence of multiple damaging variants in carriers. Of the cases, 
1,963/12,652 cases (15.5%) carried at least one damaging variant in at least one gene. Of these, 
101 cases carried damaging variants in two genes, and 1 case carried damaging variants in three 
genes. This was slightly lower than expected under a model in which damaging variants were 
randomly distributed across the cases (114.3 double and 3.4 triple carriers expected, ratio=0.86, 
p=0.082). In particular, we observed that there were significantly less carriers of damaging 
ATP8B4 variants that also carried a damaging variant in another gene (41 observed, 62.2 
expected, ratio=0.66, p=0.0028). Of the individuals who carried damaging variants in multiple 
genes, 48.0% were classified as EOAD, compared to 36.9% of the cases that carried only a single 
damaging variant (p=0.027, fisher-exact test).  
 
Discussion 
In our WES study we identified four genes in which carrying a rare deleterious variant associated 
with AD at exome-wide significance. Of these, we identified rare predicted damaging variants in 
the ATP8B4 gene as a novel AD risk factor, the other three genes were previously established AD 
risk factors, i.e. SORL1, TREM2 and ABCA7(7, 9, 20, 21). Additionally, we identified seven genes 
with suggestive evidence for an association with AD risk. Of these, the ADAM10 and ABCA1 genes 
were previously identified to be associated with AD-related mechanisms (22, 23), while for rare 
variants in the ORC6, CBX3, PRSS3, B3GNT4, and SRC genes we provide a first report for a 
suggestive association with AD risk. Almost all genes showed an increased variant burden in the 
younger cases, with the exception of the variants in CBX3 and PRSS3, which were associated with 
a protective effect. For several genes we observed trends that the rarest variants associated with 
the highest effect sizes. Also, a large fraction of the signal in SORL1, ADAM10, ABCA1, ORC6, 
B3GNT4 and SRC came from singleton variants, while in TREM2, ABCA7, ATP8B4 CBX3, and PRSS3 
the majority of the signal was carried by more common (but still rare) variants. Common 
missense variants (MAF > 1%), which occur in TREM2, SORL1 and ABCA7, had relatively small (or 
protective) effects compared to the effect size observed in the burden test. Investigation of gene-
functions indicated that most identified genes were associated with aspects of the Alzheimer 
Disease pathophysiology. 
 
Impaired SORL1 function (Sortilin Related Receptor 1) has been associated with increased Aβ 
production due to a disruption of APP processing (24, 25) and a decrease in the degradation of 
intracellular nascent Aβ peptides by lysosomes (26). In the present dataset, we identified a total 
of 168 damaging variants in the SORL1 gene, carried by 291 individuals. The association with AD 
is mainly driven by variants which are individually extremely rare and mostly singletons. The 
burden of predicted damaging SORL1 variants was highest in EOAD cases and decreased with 
increasing AAO (9, 16, 27). We observed a relationship between the predicted variant 
deleteriousness level and the effect on AD risk: LOF variants associated with a 36-fold increased 
risk of EOAD and 7-fold increased risk of LOAD, while missense variants associated with a 2.7 and 
1.9-fold increase risk of EOAD and LOAD, respectively.  
 
TREM2 (Triggering Receptor Expressed On Myeloid Cells 2) is involved in microglia-dependent 
pathophysiological processes in AD through Aβ phagocytosis and clearance and/or compaction 
in amyloid plaques (28, 29). In our dataset, we identified 17 damaging TREM2 variants carried by 
291 individuals. Although damaging TREM2 variants are rare, most variants were observed in 
several individuals, which is different from what is observed in, for example, SORL1. We found a 
clear relation with predicted variant deleteriousness and the association with AD: TREM2 LOF 
variants after refinement associated with a 10.8-fold increased risk of AD, while missense variants 
associated with a 3.5-fold increased AD risk.  
 
One of the functions of ABCA7 (ATP Binding Cassette Subfamily A Member 7) is to clear the blood 
brain barrier from Aβ (30). Impaired ABCA7 protein function was also associated with a faster 
APP endocytosis, an increased in vitro Aβ production, and an accelerated amyloid pathology 
accumulation in young transgenic mice (31-33). In our dataset, we found an AD-association of 
damaging variants in the ABCA7 gene based on 272 variants carried by 1,267 individuals. As many 
as ~7.5% of all AD cases with an AAO<70 years and 5% of all controls carried such an ABCA7 
variant. The association with AD is driven by damaging variants with different features: some are 
individually extremely rare or singletons, while others occur in several individuals. Both LOF and 
missense variants in the ABCA7 gene were associated with a ~1.4-1.8-fold increased AD risk, but 
the burden of damaging variants concentrated in younger AD patients. 
 
We identified a new signal in the ATP8B4 gene (ATPase Phospholipid Transporting 8B4) which 
encodes a member of the cation transport ATPase which is involved in phospholipid transport at 
the cell membrane.  ATP8B4 is expressed in macrophages/microglia in the brain and rare variants 
in this gene have been associated with the risk of developing systemic sclerosis, an autoimmune 
disease (34). Approximately 4% of the AD cases and 2.5% of the controls carried a rare, predicted 
deleterious variant in ATP8B4. The burden reaches exome wide significance based on 74 variants 
carried by 767 individuals. The association with AD was mainly driven by 3 missense variants 
(G395S, C874R, and H987R), while the burden of highly rare variants (allele count < 5) did not 
associate with AD. In contrast to SORL1, TREM2 and ABCA7, the variant burden was not 
associated with AAO. A common variant in the ATP8B4 locus (rs6493386) was previously 
associated with both AD risk and LDL (35, 36). A signal in the proximity of the ATP8B4 locus was 
reported in a large GWAS meta-analysis, which was tagged to the neighboring SSP2L gene (4). It 
cannot be excluded that the SSP2L association with AD might be driven by ATP8B4 rather than 
by SSP2L. Our observations highlight potential implication of ATP8B4 in inflammation and may 
provide additional support for the importance of microglia/inflammation in the AD 
pathophysiology. 
 
α-secretase ADAM10 (a disintegrin and metalloproteinase domain-containing protein 10) plays 
a major role in APP metabolism (37). In our analysis, we identified only 11 damaging ADAM10 
variants in 12 carriers. With the rare occurrence of such variants only a very strong association 
with AD will enable the detection of an exome-wide significant signal, even in the current large 
sample. Indeed, we found  that damaging LOF variants and missense variants were suggestively 
associated with a 15-fold and 6-fold increased AD-risk, respectively. In addition, similar to the 
association signals identified in SORL1 and ABCA7 genes, these LOF and high-impact missense 
variants showed suggestive association with an increased risk of EOAD. Notably, LOF variants in 
ADAM10 were previously reported to be associated with an autosomal dominant inheritance of 
abnormal pigmentation of the skin (38), such that skin pigmentation might represent a clinical 
proxy for carrying a rare LOF variant in the ADAM10 gene. We could not retrospectively 
investigate skin pigmentation in our cohort. Common variants in ADAM10 were recently 
associated with AD risk in a GWAS meta-analysis (REF), which aligns with the independent AD-
associations with common variants and rare variant-burden also observed for SORL1, ABCA7, 
and, most likely, ATP8B4 . Previous reports identified the Q170H and the R181G variants in 
ADAM10 in LOAD families (39). While we did detect these variants in our sample, the single 
variant analysis indicated that these were not significantly associated with AD.  
The role of the ABCA1 transporter (ATP Binding Cassette Subfamily A Member 1) gene, has been 
assessed extensively (40). ABCA1 protein lipidates APOE in the CNS (41), and poor ABCA1-
dependent lipidation of APOE-containing lipoprotein particles may increase Aβ deposition and 
fibrillogenesis (42). Indeed, mice overexpressing ABCA1 in an AD-like mouse model had 
significantly less Aβ deposition (41). A rare deleterious missense variant (A937V) was previously 
proposed to be implicated in a LOAD family (43) and another rare deleterious missense variant 
(N1800H) was previously associated with AD risk (44). Based on 142 variants carried by 216 
individuals, we found that the burden of rare variants in the ABCA1 gene was suggestively 
associated with increased risk of AD. This variant burden did not include the A937V and N1800H 
variants, which were previously associated with AD (43, 44), respectively due to differential 
missingness and a low REVEL score. We were able to manually include the N1800H variant in a 
post hoc analysis, which improved the association of ABCA1 from p=2.4e-5 to p=4.5e-7, crossing 
the conservative Bonferroni threshold. Damaging variants in ABCA1 associated with AD with a 
pattern similar as SORL1: early onset cases carried the highest fraction of predicted deleterious 
variants and a higher level of variant deleteriousness associated with a higher AD risk. While LOF 
variants in ABCA1 were suggestively associated with a relatively modest >4-fold increased early 
onset AD risk (i.e. compared to damaging variants in SORL1 or TREM2), the large number of 
damaging ABCA1-variants in our sample enabled the detection of the suggestive association.  
 
The protein encoded by ORC6 (Origin Recognition Complex Subunit 6) is part of a highly 
conserved six subunit protein complex essential for the initiation of the DNA replication in 
eukaryotic cells (45). It is expressed at a low level in neurons (46). We identified 15 rare damaging 
mutations in 16 individuals (14 of whom were cases), which were suggestively associated with a 
strong >9-fold increased risk for having early onset of AD, in a pattern resembling the AD-
association of damaging SORL1 variants. When this association replicates, further functional 
investigation is necessary to explain the involvement of the ORC6 protein in AD pathophysiology. 
 
The protein encoded by the B3GNT4 gene is a member of the beta-1,3-N-
acetylglucosaminyltransferase protein family. B3GNT4 was associated with serum urate and 
triglyceride concentration in GWAS (47, 48) which were both associated with increased risk for 
dementia and AD. While the protein is highly expressed in the brain (49), its function in the brain 
is not well explored. We identified 22 rare damaging mutations in 29 individuals, and the burden 
of damaging variants was highest in the early onset cases as evidenced by a suggestive >12-fold 
increased risk for early onset AD. The few variants identified included only one LOF variant, such 
that the number of variants was too low to infer a relation with variant-damagingness.  
 
The protein encoded by SRC (Proto-Oncogene, Non-Receptor Tyrosine Kinase) is a non-receptor 
protein tyrosine kinase that belongs to the same family as Pyk2, an AD genetic risk factor, and 
Fyn. Moreover, SRC is known to bind Pyk2, which is critical for Pyk2 activity (50) SRC is activated 
by many different classes of cellular receptors including immune response receptors, integrins 
and other adhesion receptors (51) The suggestive AD-risk increasing signal in SRC-variants was 
based on 15 damaging variants carried by 27 individuals, and the strongest association was found 
in early onset cases (OR=6.6). SRC has been described to potentially modulate APP 
trafficking/metabolism (52), but also Tau phosphorylation (53). 
 
We identified a single variant in the CBX3 gene (Chromobox 3) that suggestively associated with 
a decreased AD risk, with an odds ratio of 0.2. The variant was carried by 30 individuals, mostly 
controls and several EOAD cases. The protein encoded by CBX3 binds DNA and is a component 
of heterochromatin (54). it is ubiquitously present and, in the brain, mainly expressed in neurons 
(46). Little is known about CBX3 functions in the brain and this protein has been described to 
maintain lineage specificity during neural differentiation (55), as well as promoting glioma cell 
proliferation (56). The CBX3 variant was previously identified to have a suggestive signal in an AD 
WES sequencing analysis (which included overlapping samples with this study)(12). 
 
Last, we identified a suggestive association between variants in the PRSS3 (Serine Protease 3) 
gene and two-fold decreased risk for AD (OR=0.5). We identified 21 variants in this gene carried 
by 111 individuals, of which 14 were singletons. This indicates that the majority of this protective 
signal was effectuated by more common (but still rare) variants. PRSS3 encodes a serine protease 
of the trypsin family which is mainly expressed in pancreas and in the neurons of the brain (46). 
The Kunitz inhibitor domain in APP has been reported to be a highly specific substrate of the 
PRSS3 protease (57), but the protective effect of these variants needs to be replicated and further 
explored in future studies. 
 
This comparison of between exomes from AD cases and controls represents one of the largest 
performed thus far, which allows the detection of differential burden of damaging variants in 
genes that were not yet associated with AD. Across all genes, a large part of the signal depended 
on singletons, indicating that high level of accuracy is warranted. We applied several approaches 
to maximize the statistical power and the accuracy of the discovery study. (i). We collected and 
merged raw WES data on one server which allowed us to uniformly apply a quality control 
pipeline. (ii) We designed custom algorithms that detected and removed the prevalent batch 
effects across all data simultaneously, which were highly prevalent due to the use of different 
WES kits and sequencing laboratories. (iii). We confirmed that the variants were not somatic by 
checking allele balance, indicating that the protective signal in PRSS3 and CBX3 was not a 
consequence of age-related clonal hematopoiesis (ARCH) in our controls (58), who were on 
average older than our cases. (iv). We were able to accommodate differential variant effects by 
performing burden analyses across four different levels of predicted variant deleteriousness. (v). 
We took into consideration that cases with a higher age at onset may have a lower burden of 
damaging variants.  
Further, we performed several complementary analyses to explore additional potential biases. 
(vi). In an age-matched analysis we investigated whether burden associations with AD could also 
be due to a confounding factor such as age. This analysis supported a role in AD for all the eleven 
genes. (vii) A sensitivity analysis in which we compared our results when corrected and 
uncorrected for APOE-ε4 indicated that the observed associations between variant burden and 
AD risk are independent of APOE genotype. We could not explore possible synergistic or additive 
effects between carrying a damaging genetic variant in one of the identified genes and APOE 
genotype, because part of our sample was selected according to APOE genotype, which 
complicates such an analysis. Moreover, stratification by APOE genotype would reduce statistical 
power. 
 
In conclusion, our study provides further evidence for a pivotal role of APP processing, lipid 
metabolism, and microglia and neuroinflammatory processes in AD pathophysiology (59-61). Of 
the genes identified here, five belong to the Aβ network, either through Aβ production (APP 
processing) or through increased aggregation / decreased clearance. More specifically, the 
suggestive association of rare variants in ADAM10 with increased AD risk is in line with the 
important role of APP processing on top of the contribution of APP, PSEN1, PSEN2, SORL1 and 
ABCA7. Furthermore, next to the known AD-associations of variants in APOE, PLCG2, ABI3, ABCA7 
and TREM2, we find a suggestive association of rare variants in ABCA1 with AD risk, providing a 
novel genetic determinant with a role in Aβ aggregation and clearance. Moreover, with the 
identification of  ATP8B4 as a novel AD genetic risk factor, further strengthening the evidence for 
the involvement of microglia and neuroinflammation in AD. We acknowledge that the novel 
genetic associations we identified will require further investigation and replication in 
independent samples before they can be accepted as genuine AD genetic determinants. Notably, 
with this sample we were able to assess 13,299 genes of the total 19,822 autosomal protein-
coding genes and not all types of genetic variation. A larger sample size and the use of whole 
genome sequencing will allow the investigation of even more genes, which will require continued 
efforts in combining and jointly analyzing samples. 
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Table 1 
gene 
deleteriousness 
threshold p-value FDR 
#variants / 
#carriers 
carrier frequency odds ratio (95% CI) age at onset 
EOAD / LOAD / control case / control EOAD / control LOAD / control median (IQR) 
SORL1 LOF+REVEL≥50 1.80E-18 <<0.01% 168 / 291 2.66% / 1.45% / 0.67% 2.6 (2.1-3.3) 3.6 (2.7-4.9) 2.1 (1.5-2.8) 67 (60-74) 
LOF 9.00E-16  38 / 49 0.81% / 0.16% / 0.02% 16.4 (9.0-29.8) 36.1 (10.8-inf) 7.2 (2.0-50.9) 60 (56-68) 
REVEL 50-100 4.80E-10  130 / 245 1.92% / 1.29% / 0.64% 2.2 (1.7-2.8) 2.7 (2.0-3.8) 1.9 (1.4-2.6) 68 (60-75) 
REVEL 50-100 [refined] 6.20E-12  129 / 261 2.02% / 1.44% / 0.63% 2.5 (1.9-3.2) 3.0 (2.1-4.1) 2.2 (1.6-3.0) 68 (60-75) 
TREM2 LOF+REVEL≥25 2.80E-16 <<0.01% 17 / 291 2.12% / 1.83% / 0.55% 3.6 (2.8-4.6) 4.2 (2.9-6.0) 3.4 (2.4-4.7) 70 (63-76) 
LOF 7.60E-03  9 / 39 0.25% / 0.26% / 0.08% 3.3 (1.7-6.5) 3.4 (1.3-9.0) 3.3 (1.4-7.7) 72 (63-76) 
LOF [refined] 4.70E-03  8 / 21 0.20% / 0.14% / 0.01% 10.8 (4.4-26.9) 14.2 (3.3-460.5) 9.4 (2.6-320.4) 70 (63-75) 
REVEL 25-100 8.90E-15  8 / 253 1.87% / 1.58% / 0.47% 3.7 (2.8-4.8) 4.3 (2.9-6.4) 3.4 (2.4-4.9) 69 (63-76) 
REVEL 25-100 [refined] 9.00E-20  10 / 336 2.56% / 2.04% / 0.66% 3.5 (2.8-4.4) 4.4 (3.1-6.1) 3.2 (2.3-4.3) 69 (63-76) 
ABCA7 LOF+REVEL≥25 8.80E-08 0.06% 272 / 1267 7.41% / 6.15% / 5.04% 1.3 (1.2-1.5) 1.5 (1.3-1.7) 1.3 (1.1-1.4) 70 (62-78) 
LOF 1.50E-03  47 / 107 0.81% / 0.54% / 0.32% 1.8 (1.2-2.6) 2.2 (1.4-3.7) 1.5 (1.0-2.4) 69 (60-74) 
REVEL 25-100 4.20E-06  225 / 1162 6.60% / 5.62% / 4.73% 1.3 (1.2-1.5) 1.4 (1.2-1.7) 1.2 (1.1-1.4) 70 (62-79) 
REVEL 25-100 [refined] 4.10E-08  223 / 983 5.91% / 4.91% / 3.69% 1.4 (1.3-1.6) 1.6 (1.4-1.9) 1.3 (1.2-1.6) 70 (62-78) 
ATP8B4 LOF+REVEL≥25 4.60E-07 0.24% 74 / 767 4.43% / 4.12% / 2.68% 1.5 (1.3-1.8) 1.6 (1.3-1.9) 1.5 (1.3-1.8) 72 (62-79) 
LOF 2.10E-01  13 / 34 0.25% / 0.16% / 0.12% 1.5 (0.7-3.1) 1.8 (0.7-4.4) 1.4 (0.6-3.1) 73 (59-78) 
REVEL 25-100 1.10E-06  61 / 733 4.19% / 3.96% / 2.57% 1.5 (1.3-1.8) 1.6 (1.3-1.9) 1.5 (1.3-1.8) 72 (63-79) 
ADAM10 LOF+REVEL≥75 2.70E-06 1% 11 / 12 0.25% / 0.01% / 0.01% 7.3 (1.3-46.0) 19.8 (4.3-inf) 1.1 (0.0-32.2) 62 (59-64) 
LOF 2.40E-04  9 / 9 0.17% / 0.01% / 0.01% 5.4 (1.6-17.9) 13.4 (2.9-inf) 1.1 (0.0-28.7) 63 (59-64) 
REVEL 75-100 0.0016  2 / 3 0.07% / 0.00% / 0.00% -- -- -- -- 
ABCA1 LOF+REVEL≥50 2.50E-05 6.5% 142 / 216 1.55% / 1.05% / 0.72% 1.7 (1.3-2.3) 2.3 (1.6-3.2) 1.5 (1.1-2.1) 70 (59-76) 
LOF 5.70E-03  21 / 31 0.22% / 0.15% / 0.10% 3.2 (1.5-6.8) 4.2 (1.5-12.0) 2.7 (1.0-7.3) 70 (59-77) 
LOF [refined] 2.50E-03  20 / 24 0.22% / 0.14% / 0.03% 4.9 (2.1-11.4) 6.9 (1.8-25.9) 4.0 (1.1-14.4) 68 (59-77) 
REVEL 50-100 6.20E-04  121 / 185 1.33% / 0.90% / 0.62% 1.6 (1.2-2.2) 2.0 (1.4-3.0) 1.4 (1.0-2.0) 69 (59-76) 
REVEL 50--100 [refined] 1.20E-06  122 / 230 1.70% / 1.23% / 0.63% 2.1 (1.6-2.7) 2.5 (1.7-3.5) 1.9 (1.3-2.6) 68 (58-76) 
ORC6 LOF+REVEL≥25 5.60E-05 12% 15 / 16 0.27% / 0.03% / 0.02% 4.1 (1.3-24.7) 9.4 (3.1-84.2) 1.3 (0.2-12.9) 60 (59-65) 
LOF 5.10E-02  4 / 4 0.07% / 0.00% / 0.01% -- -- -- -- 
REVEL 25-100 0.00042  11 / 12 0.20% / 0.03% / 0.01% 6.4 (1.9-21.3) 13.3 (3.1-inf) 2.7 (0.4-82.7) 61 (59-67) 
CBX3 LOF+REVEL≥25 6.00E-05 12% 1 / 30 0.12% / 0.02% / 0.26% 0.2 (0.1-0.3) 0.3 (0.1-0.9) 0.1 (0.0-0.3) -- 
PRSS3 LOF+REVEL≥25 7.60E-05 14% 21 / 111 0.27% / 0.43% / 0.72% 0.5 (0.3-0.7) 0.3 (0.2-0.7) 0.6 (0.4-0.9) -- 
B3GNT4 LOF+REVEL≥25 9.50E-05 16% 22 / 29 0.32% / 0.16% / 0.02% 8.1 (2.4-32.1) 12.6 (4.0-97.8) 6.0 (2.1-53.3) 66 (60-74) 
SRC LOF+REVEL≥50 1.10E-04 18% 15 / 27 0.32% / 0.10% / 0.06% 3.3 (1.5-7.4) 6.6 (2.3-18.8) 1.9 (0.6-5.8) 64 (58-73) 
 Results from the discovery analysis. Per gene, results are shown for the most significant 
deleteriousness threshold, and separately for LOF variants and missense variants (except for 
CBX3, PRSS3, B3GNT4, SRC which have ≤1 LOF variant carrier). A carrier is an individual with at 
least one or more minor alleles. Carrier frequency is the percentage of people that carry one or 
more variants. Tests were performed at the gene level, putatively gathering several transcripts 
of a same gene. 
 
 
 
Figure 1 
  
 
A) Sample QC We removed (1) samples with very low read coverage, (2) samples with excessive 
contamination, (3) samples for which the gender-annotation did not fit with the sex-
chromosomal profile, (4) samples that were non-Caucasian, (5,6) samples with an excess of novel 
SNPs or indels, (7) samples that deviated in heterozygous/homozygous or transition/transversion 
ratios, (8) closely related samples (IBD), and (9) samples that were on PCR-plates that were 
enriched for gender-annotation mismatches, (10) removal of samples that carried variants 
classified as pathogenic or likely pathogenic in Mendelian dementia genes (see supplemental 
data). (11) samples with a mismatch between Braak stage and AD label (AD case with Braak stage 
<= 1 or a control with Braak stage >= 5) or were not annotated as an AD case or control.  
B) Variant QC, Multi-allelic SNPs were split into bi-allelic variants. (1) Variants that were in close 
vicinity, in cis and always occurred together, were merged into single events. (2) We designed a 
custom tool (see supplement to remove G>T and C>A variants, caused by the oxygenation of G 
bases (62). (3) Exclusion of variants in simple tandem repeat (STR) regions and low complexity 
regions (LCR). (4) Exclusion of variants that deviated in allele read balance (<0.25 or >0.75 for 
heterozygous calls and <0.9 for homozygous calls. (5) Exclusion of variants for which 
heterozygous calls had <20% of the coverage of reference calls. (6) Exclusion of variants that 
deviated from Hardy-Weinberg equilibrium in controls (p < 5 * 10e-8). (7) Exclusion of variants 
that failed VQSR (>99.5% tranche for SNPs, >99% tranche for indels). (8) Exclusion of variants that 
still presented batch effects that were not explainable by population structure or phenotype 
effects using a custom tool (see supplement). C) Variant selection. (1) variants in autosomal 
protein-coding genes that were annotated by VEP (version 94.5)(63), (2) selection of variants that 
directly affected the protein (missense or LOF annotation). (3) Missense variants with a REVEL 
score (Rare Exome Variant Ensemble Learner) (13) and LOF variants were annotated using 
LOFTEE (15). Selection of missense variants with a score ≥ 25 (score range 0 - 100). and LOF 
variants with a LOFTEE ‘high-confidence’ flag, and a VEP ‘high impact’ flag. (4) Selection of 
variants that were estimated to have at least one carrier, and had a minor allele frequency (MAF) 
of <1%. (5) Selection of variants with <20% genotyping missingness (genotypes with a read depth 
< 6 are considered missing) that passed a filter for differential missingness between the EOAD, 
LOAD and control groups. Variants were divided in 4 deleteriousness categories.  
 
In colors the deleteriousness categories (translucent) used to construct the deleteriousness 
thresholds (opaque). Four different deleteriousness thresholds were used to perform burden 
tests. Of the missense variants, 572 were also classified as LOF variants and assigned to the LOF 
category.  
  
 Figure 2  
 
The number of genes tested per variant threshold. Only autosomal genes with a cumulative 
Minor Allele Count (cMAC) ≥10 were tested. 
 
 
Figure 3  
 
Quantile-quantile plot of observed p-values versus expected p-values in the absence of signal 
(log10 scale). In total, results of 31,568 different tests are shown, which were performed for 
13,299 genes. For each gene, the most significant test is shown opaque, tests for which the 
signal was less significant were shown translucent. Multiple testing correction thresholds are 
shown for suggestive and conservative thresholds. Color indicates if burden is enriched in cases 
(‘Damaging’) or controls (‘Protective’). 
 
 
Figure 4  
 
a) Odds ratios (ordinal test) per variant category. Significance is indicated if a trend in odds 
ratios was observed (i.e. a larger effect in the high deleteriousness categories and lower effect 
in lower deleteriousness categories). For missense variants, deleteriousness categories were 
merged when one category for REVEL (not LOF) categories if they had < 5 carriers; this was 
done, both for the visualization and the tests. When there were multiple neighboring 
deleteriousness categories to merge with, we merged with the smallest (in terms of carriers). 
Odds ratios for deleteriousness categories with 0 carriers and odds ratios with 0-inf confidence 
intervals are not shown. Categories with dashed confidence interval lines were not included in 
the most significant variant category. *: FDR < 0.05, **: FDR < 0.01, ***: FDR < 0.001. b) Age at 
onset per deleteriousness category and 95% CI. When the number of carrier cases per 
deleteriousness category was <10 carriers, the age at onset of these carriers was shown as 
individual dots. 
 
 
 
  
Figure 5  
 
a) Carrier frequency by age at onset. Carriers have a cumulative dosage >0.5 b) Odds ratio by 
age. Odds ratios are calculated by multinomial logistic regression. Results are shown for 
variants in the most significant deleteriousness threshold (indicated below the gene names). 
The significance symbols indicate if there is a trend towards higher enrichment in younger 
patients (see methods). *: FDR < 0.05, **: FDR < 0.01, ***: FDR < 0.001. 
 
 
 
 Figure 6  
 
a) Cumulative minor allele count by variant frequency For each gene, the number of variants 
(minor alleles) detected in cases and controls in the predicted damagingness levels threshold 
associated with the most significant association with AD (indicated at the top). Variants were 
binned according to “allele count”, the occurrence of each unique variant in the sample (from 
extremely rare singletons to more common variants with more than 10 carriers). The number 
above each bar is the number of unique variants in the bin. b) Odds ratio by variant frequency. 
For the same variants and bins as in A), the odds ratio of the AD association and its confidence 
interval is shown. Odds ratios are not shown for bins with less than 5 carriers.  
 
 
 
Figure 7 
 
Odds ratios (logistic test) for LOF and missense variants after refinement analysis. Case/control 
(+95%CI), as well as EOAD- and LOAD-specific odds ratios are shown for variant categories with 
≥5 carriers.  
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Supplemental tables 
Table S1: Sample-characteristics per contributing study 
 
 Samples Gender (%female) Case/Control APOE genotype Diagnostic validation 
 
before 
QC (#) 
after 
QC (#) 
Cases Controls  EOAD LOAD Controls Cases Controls Neuro- 
patho- 
logy CSF Clinical study % % % cases # AAO # AAO # ALS % E4 % E4 
France  
ADES-FR 3318 3254 63.1% 58.7% 61.4% 1068 59.0 930 78.2 1256 75.5 28.9% 11.6% 15 624 2615 
Germany  
AgeCoDe-UKBonn 394 371 68.4% - 99.7% 98 59.0 272 84.7 1 - 24.3% 50.0% 0 0 371 
Spain  
Barcelona SPIN 60 59 44.0% 44.4% 84.7% 50 57.3 0 N/A 9 72.8 3.0% 16.7% 37 13 9 
The Netherlands  
100-plus Study 276 254 84.4% 71.6% 25.2% 0 NA 64 101.5 190 102.9 7.0% 8.7% 0 0 274 
ERF Study 1325 400 50.0% 57.3% 1.0% 1 - 3 75.8 396 48.1 50.0% 17.0% 0 0 400 
AC-ERC 81 70 54.3% NA 100.0% 57 57.0 13 69.1 0 NA 44.3% NA 3 40 27 
Rotterdam Study 2699 1891 68.9% 55.4% 19.4% 1 - 366 83.5 1524 82.7 25.8% 14.0% 0 0 1891 
ADC-Amsterdam 518 483 55.1% NA 100.0% 341 57.3 142 68.6 0 NA 30.6% NA 0 483 0 
United Kingdom  
PERADES1 4936 4140 58.3% 57.2% 83.3% 1265 58.1 2185 76.7 690 81.5 31.6% 12.0% 0 0 4140 
CBC 471 363 54.1% 40.1% 30.6% 33 60.1 78 76.8 252 75.8 36.8% 18.7% 363 0 0 
UCL-DRC EOAD 539 409 54.8% NA 100.0% 389 54.9 20 76.6 0 NA 29.7% N/A 7 35 367 
Europe total  
ADES 15088 12057 60.2% 55.7% 62.1% 3336 57.4 4151 79.0 4570 77.5 29.7% 13.5% 788 1195 10094 
United States  
ADSP2 11365 9651 57.6% 58.3% 54.7% 757 62.4 4519 77.2 4375 86.5 23.7% 7.2% 0 0 9651 
  
Total 25,982 21,345 59.2% 57.5% 59.3% 4060 58.8 8,592 77.9 8693 82.1 26.9% 10.1% 425 1195 19745 
 
Characteristics of the samples contributed by each study, grouped by country. A.A.O: 
mean age at onset; A.L.S. mean age at last screening. 1The PERADES sample is UK-
based, but also includes samples from Spain and Italy. 2The ADSP cohort is composed 
of cohorts from the ADGC and CHARGE consortia. 
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Table S2: Capture kits used by the contributing studies. 
Study Capture kits (#samples, after QC) 
France  
ADES-FR Agilent V1: 6,Agilent V3: 10,Agilent V4: 119, 
Agilent V4UTR: 14,Agilent V5UTR: 789, 
Agilent V5: 1362, WGS: 954 
Germany  
AgeCoDe-UKBonn Nimblegen V2: 371 
Spain  
Barcelona SPIN Nimblegen V3: 59 
The Netherlands  
100-plus Study Agilent V6: 40,Nimblegen V3: 214 
ERF Study Agilent V4: 400 
AC-ERC Nimblegen V2: 70 
Rotterdam Study Nimblegen V2: 1891 
ADC-Amsterdam Agilent V6: 180,Nimblegen V3: 303 
United Kingdom  
PERADES1 Nextera v1.2: 4140 
CBC Nimblegen V2: 63, 
Multiplex Illumina TruSeq v2: 100, 
Multiplex Illumina TruSeq: 200 
UCL-DRC EOAD Sureselect: 5, Haloplex: 404 
United States  
ADSP-BCM WGS: 11, Nimblegen VCRome v2.1: 2186 
ADSP-Broad Institute WGS: 16, Illumina Rapid Capture Exome: 4112 
ADSP-WUGSC WGS: 36, Nimblegen VCRome v2.1: 3290 
WGS=whole genome sequencing.  
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Table S3: Single variant analysis. 
 
Gene 
Transcripts 
(canonical=bold) 
 
SNP id 
Burden 
outlier 
FDR 
Case/Control  
Protein change (per transcript) 
(bold: name in text) 
 
Original reason 
for exclusion 
 
REVEL 
 
LOF 
 
MAF 
Refinement 
analysis 
bold=action 
italic=reason for 
rejection 
 
FDR 
OR (95%CI) 
SORL1 
ENST00000260197: A 
ENST00000525532: B 
ENST00000534286: C 
ENST00000532694: D 
ENST00000527934: E 
rs2298813 NA 4% 1.16 (1.05-1.27) A: A528T MAF/REVEL 11  4.9% too common 
rs140384365 NA 20% 2.49 (1.22-5.07) A: V1459I, B: V403I, C: V369I, 
D: V305I, E: V74I 
REVEL 9  0.08% added 
rs143536682 6.3% 79% 0.53 (0.19-1.47) A: S2175R, B: S1119R, C: S1085R, 
D: S1021R, E: S790R 
 81  0.04% removed 
TREM2 
ENST00000373113: A 
ENST00000373122: B 
ENST00000338469: C 
rs75932628 84% <<1% 3.74 (2.84-4.92) A,B,C: R47H  34  0.54% kept 
rs143332484 NA <<1% 1.58 (1.32-1.88) A,B,C: R62H MAF/REVEL 4  1.3% too common 
rs142232675 NA 1% 2.63 (1.56-4.45) A,B,C: D87N REVEL 20  0.15% added 
rs2234255 NA 1% 6.39 (2.68-15.2) A,B,C: H157Y REVEL 0  0.05% added 
rs538447052 11% 20% 1.91 (0.71-5.08) B: splice acceptor variant  NA HC 0.04% removed 
rs2234256 NA 2% 2.27 (1.34-3.86) A: L211P REVEL 0  0.15% added 
rs2234258 NA 20% 2.28 (0.90-5.78) C: W191X (stop gained) REVEL NA LC 0.05% low OR 
ABCA7 
ENST00000263094: A 
ENST00000433129: B 
ENST00000435683: C 
rs546173555 5.0% 89% 1.09 (0.37-3.20) A,B: R19W  54  0.04% removed 
rs201665195 100% <1% 3.67 (2.10-6.42) A,B: L101R  28  0.18% kept 
rs72973581 NA 2% 0.89 (0.81-0.97) A,B: G215S, C: G77S MAF/REVEL 16  5.6% too common 
rs3764647 NA 2% 0.85 (0.76-0.95) A,B: H395R, C:H257R MAF/REVEL 18  3.5% too common 
rs547447016 NA NA 2.01 (1.35-3.01) A,B: EEQ708-710X, C: EEQ570-572X diff. miss NA HC 0.27% QC 
rs117187003 1.8% 47% 0.84 (0.61-1.15) A,B: V1599M, C: V1461M  58  0.41% removed 
rs4147918 NA 1% 0.84 (0.76-0.94) A,B: Q1686R, C:Q1548R MAF/REVEL 15  3.6% too common 
rs200538373 NA NA 1.67 (1.23-2.28) A,B,C: c.5570+5G>C  diff.miss/REVEL NA Lit. 1   0.43% QC 
ATP8B4 
ENST00000284509: A 
ENST00000559829: B 
rs74811880 99% 5% 3.14 (1.55-6.34) A,B: H987R  26  0.08% kept 
rs74012834 55% 7% 1.41 (1.05-1.91) A,B: C874R  25  0.45% kept 
rs138799625 99% <<1% 1.83 (1.48-2.26) A,B: G395S  86  0.92% kept 
ABCA1 
ENST00000374736: A 
rs2066715 NA 17% 0.93 (0.85-1.01) A: V825I MAF/REVEL 0  6.1% too common 
rs2066714 NA 2% 0.91 (0.86-0.97) A: I883M MAF/REVEL 0  13.3% too common 
rs140365800 4.8% 74% 0.81 (0.29-2.22) A: D1018G  84  0.04% removed 
rs143180998 NA 13% 0.49 (0.25-0.96) A: A1182T REVEL 17  0.09% protective 
9:107565564:
C>A 
0.3% NA 0.94 (0.19-4.52) A: splice donor variant  NA HC 0.02% removed 
rs150125857 NA 13% 2.75 (1.27-5.95) A: R1680Q REVEL 0  0.07% added 
rs146292819 NA 2% 4.16 (2.02-8.56) A: N1800H REVEL 0  0.08% added 
CBX3 
ENST00000409747: A 
rs142550836 100% <<1% 0.16 (0.08-0.34) A: N74S  36  0.07% kept 
PRSS3 
ENST00000361005: A 
ENST00000379405: B 
ENST00000342836: C 
ENST00000429677: D 
rs143209949 12% 34% 0.75 (0.41-1.38) A:R125C, B:R68C, C: R82C, D:R61C  53  0.11% kept 
 
See detailed gene discussion for explanation. Variants are shown that are i) included in 
the burden but considered outliers (outlier FDR < 20%, fisher exact test), ii) are a 
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missense or LOF variant and associated with AD (case/control FDR < 20%, logistic 
regression), iii) are mentioned in the text for other reasons.  Refinement was only 
performed with variants from the first two categories. LOF: LC/HC: LOFTEE low/high 
confidence classification, Lit: based on literature this variant is known to be a LOF variant 
in ABCA7, but this was not recognized by LOFTEE. Refinement analysis: variants that 
were common (MAF > 1%), or had the opposite effect were not considered for the refined 
burden test.  
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Supplemental figures 
Figure S1: Age, gender, APOE genotype distribution 
 
 
Age, gender and APOE genotype distribution of all samples, stratified by case/control 
status.  
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Figure S2: Sensitivity Analysis: AD vs Age association 
 
Sensitivity analysis of the gene burden tests (for the most significant deleteriousness 
thresholds, Table 1). Comparison of the case/control odds ratio of an age-matched and 
a normal analysis. Age-matching was performed as described in the methods.  
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Figure S3: Read length per study 
 
 
Read length.  
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Figure S4: Genotype Quality 
 
Fraction of genotype calls with a genotype quality < 40. Each sample is evaluated in 
context of its capture kit. Samples that are considered outliers due to missingness or 
contamination are indicates with a red ‘*’ symbol.   
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Figure S5: Genetic sex 
 
Sex chromosome copy number versus gender annotation. Samples that failed the sex 
check were plotted last. Samples that were classified as XXY, XXY and XXX are indicated 
by respectively right, down and upwards pointing triangle symbols.  
 
 14 
Figure S6: PCA: Sample population compared to 1,000G population samples 
 
First two PCA components of the study samples, together with 1000 genome samples for reference. Samples in red are 
considered population outliers. 
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Figure S7: first two population PCA components per study 
 
First two PCA components per study. Samples indicated as a ‘x’ are outliers.  
 16 
Figure S8: Third and fourth population PCA components per study 
 
Third and fourth PCA component for each study. Samples indicated as a ‘x’ are outliers. 
 17 
Figure S9: Number of novel SNPs (union of capture kits) 
 
Nr. of novel SNPs in the region representing the union of all capture kits + 100bp padding. 
Sample QC outliers (step 5-8) are shown as red stars. Variants are classified as novel if 
they are not present in DBSNP v150. Per geographical region, the comprehensiveness 
of the annotation of local rare variants in DBSNP might vary. 
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Figure S10: Number of novel indels per study (union of capture kits) 
 
Nr. of novel indels in the region representing the union of all capture kits + 100bp padding. 
Sample QC outliers (step 5-8) are shown as red stars. Variants are classified as novel if 
they are not present in DBSNP v150. Per geographical region, the comprehensiveness 
of the annotation of local rare variants in DBSNP might vary. 
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Figure S11: Number of novel SNPs (intersection of capture kits) 
 
Nr. of novel SNPs in the intersection of all capture kits. Sample QC outliers (step 5-8) are 
shown as red stars. Variants are classified as novel if they are not present in DBSNP 
v150. Per geographical region, the comprehensiveness of the annotation of local rare 
variants in DBSNP might vary. 
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Figure S12: Number of novel indels (intersection of capture kits) 
 
Nr. of novel indels in the intersection of all capture kits. Sample QC outliers (step 5-8) are 
shown as red stars. Variants are classified as novel if they are not present in DBSNP 
v150. Per geographical region, the comprehensiveness of the annotation of local rare 
variants in DBSNP might vary. 
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Figure S13: Ts/Tv ratio known variants (intersection capture kits) 
 
Ts/Tv of known variants in the region covered by all capture kits. Sample QC outliers 
(step 5-8) are shown as red stars. Variants are classified as known if they are present in 
DBSNP v150. 
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Figure S14: Ts/Tv ratio novel variants (intersection of capture kits) 
 
Ts/Tv of novel variants in the region covered by all capture kits. Sample QC outliers (step 
5-8) are shown as red stars. The distribution is wide due to a low number of novel SNPs 
per sample (Figure S11). Ts/Tv values are for plotting purposes maximized at 8. Variants 
are classified as novel if they are not present in DBSNP v150. 
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Figure S15: Het/Hom ratio known variants (intersection capture kits) 
 
Het/Hom of known variants  in the region covered by all capture kits. Sample QC outliers 
(step 5-8) are shown as red stars. Variants are classified as known if they are present in 
DBSNP v150. Low het/hom ratios can be an indication of inbreeding, while high het/hom 
ratios can be an indication of contamination. The problem of contamination is mostly 
limited to more common variants, and not the rare variants that are the focus of this study
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Figure S16: First two PCA components per study, after sample QC. 
 
All analysis are corrected for the first 6 PCA components.  
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Figure S17: Third and fourth PCA components per study, after sample QC. 
 
All analysis are corrected for the first 6 PCA components.  
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Figure S18: Fifth and sixth PCA components per study, after sample QC. 
All analyses are corrected for the first 6 PCA components. 
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Supplemental methods 
We analyzed a total sample of 25,982 individuals sequenced with Illumina technology. Of 
these, 15,088 individuals were collected as part of the Alzheimer Disease European 
Sequencing consortium (ADES), comprising 11 studies from Germany, France, The 
Netherlands, Spain, and the United Kingdom. All studies were approved by the ethics 
committees of respective institutes, and all participants provided informed consent for 
study participation. These samples were combined with 11,365 samples from the 
Alzheimer’s Disease Sequencing Project (ADSP), which were described previously2 
(Table S1).  
 
Across all studies, AD cases were defined according to NIAA criteria3 for possible or 
probable AD or according to NINCDS-ADRDA criteria4 depending on the date of 
diagnosis. When possible, supportive evidence for an AD pathophysiological process was 
sought (including CSF biomarkers) or the diagnosis was confirmed by neuropathological 
examination (Table S1). Cases were annotated with the age at onset or age at diagnosis 
(2014 samples), otherwise, samples were classified as late onset AD (366 samples). 
Controls were not diagnosed with AD. All contributing datasets were sequenced using a 
paired-end Illumina platform, but different exome capture kits were used, and a subset of 
the sample was sequenced using whole genome sequencing (Figure S1, Table S2).  
Sample descriptions 
ADES-FR 
The ADES-FR project combines WES and WGS data from AD cases and controls from 
France5. Part of the patients are from the CNRMAJ-Rouen center (n=921) and patient 
ascertainment is described in detail in Nicolas et al.6 including an update of the inclusions 
by the French National network CNR-MAJ (national reference center for young Alzheimer 
patients). Briefly, unrelated cases with early-onset AD (age at onset ≤65 years) from 
France were recruited among patients who fulfilled the NIAA criteria3. The clinical 
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examination included personal medical and family history assessment, neurologic 
examination, neuropsychological assessment, and neuroimaging. In addition, 
cerebrospinal fluid (CSF) biomarkers indicative of AD were available for 67% of the cases. 
Cases with CSF biomarkers not consistent with  AD diagnostics were excluded. A positive 
family history (i.e., at least a secondary case among first- or second-degree relatives, 
whatever the age of onset) was present in 45% of cases. Patients were either screened 
by Sanger sequencing and QMPSF for pathogenic variants in APP, PSEN1 or PSEN2 
prior to WES or by the interpretation of WES data or both. Carriers of pathogenic variants 
were not included for WES or were secondarily excluded following WES analysis so that 
none of the CNRMAJ-Rouen patients included in this work prior to shared analyses is a 
carrier of a pathogenic variant in APP, PSEN1, PSEN2 as well as in a list of Mendelian 
dementia causative genes7. In addition, some controls were recruited directly from the 
CNRMAJ (n=30). A large part of the samples was from the European Alzheimer’s Disease 
Initiative (EADI) dataset8. This study combined clinical prevalent and incident cases of 
AD (n=1,121) (i) from Lille cross-sectional studies and (ii) from the Three-City (3C) study, 
a population-based, prospective study with 12-years of follow-up9. Diagnoses were 
established according to the DSM-III-R and NINCDS-ADRDA criteria4. Controls were 
selected among the 3C individuals not diagnosed with dementia after a 12-year follow-up 
(n=670). In addition, other controls were obtained from the FREX consortium. These 
controls (n=576) were specifically designed from 6 French cities with the aim of studying 
and establishing the French population genetic structure of rare variants. Overall, the 
ADES-FR samples includes 2,042 AD cases (1,088 EOAD and 954 LOAD) and 1,276 
controls. All patients and controls provided informed written consent for genetic analyses 
in a clinical and/or in a research setting, according to each study. In addition, the ethics 
committee of the Rouen University Hospital approved the use of retrospective data in the 
context of the ADES-FR project and with other ADES European and American partners 
(CERNI notifications 2017-015 and 2019-055). 
 
 29 
AgeCoDe-UKBonn  
The AgeCoDe-UKBonn sample was derived from the following two sources, the German 
study on Aging, Cognition, and Dementia in primary care patients (AgeCoDe, n=294) and 
the interdisciplinary Memory Clinic at the University Hospital of Bonn (UKBonn, n=100). 
The German study on Aging, Cognition, and Dementia: The AgeCoDe study is a 
multicenter prospective general practice-based cohort study since 2001, including 
community dwelling elderly aged 75 years or older that were recruited at six study sites 
(Bonn, Düsseldorf, Hamburg, Leipzig, Mannheim, and Munich). The AgeCoDe study was 
approved by the local ethics committees of the Universities of Bonn, Hamburg, 
Düsseldorf, Heidelberg/Mannheim, Leipzig, and Munich. Before participation written 
informed consents were collected from all subjects. The AgeCoDe study aims to identify 
risk factors and predictors of cognitive decline and dementia10,11. Participants were 
recruited from general practitioner (GP) registries. Inclusion criteria were an age of 75 
and older, absence of dementia, one or more visits to the GP in the past year, no hearing 
or vision impairments and German as a native language. Exclusion criteria were only 
home-based GP consultations, severe illness with a fatal outcome within 3 months and a 
language barrier. The baseline assessment including 3,327 subjects was completed 
between 2002 and 2003. After the baseline assessment 70 subjects were excluded due 
to presence of dementia after standard assessment and 40 subjects were excluded with 
an age below 75 years. Participants were interviewed for follow up every 18 months. All 
assessments are performed at the participant’s home by a trained study psychologist or 
physician. At all visits, assessment includes the Structured Interview for Diagnosis of 
Dementia of Alzheimer type, Multi-infarct Dementia, and Dementia of other etiology 
according to DSM-IV and ICD-10 (SIDAM)12. The SIDAM comprises: (1) a 55-item 
neuropsychological test battery, including all 30 items of the MMSE and assessment of 
several cognitive domains (orientation, verbal and visual memory, intellectual abilities, 
verbal abilities/ calculation, visual–spatial constructional abilities, aphasia/ apraxia); (2) a 
14-item scale for the assessment of the activities of daily living (SIDAM-ADL-Scale); and 
(3) the Hachinski Rosen-Scale. Dementia was diagnosed according to DSM-IV criteria. 
AgeCoDe provided DNA from 294 persons who progressed to late onset AD dementia at 
any follow up. 
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UKBonn: The interdisciplinary Memory Clinic of the Department of Psychiatry and 
Department of Neurology at the University Hospital in Bonn provided early-onset AD 
patients (n=100). Diagnoses were assigned according the NINCDS/ADRDA criteria4 and 
on the basis of clinical history, physical examination, neuropsychological testing (using 
the CERAD neuropsychological battery, including the MMSE), laboratory assessments, 
and brain imaging. 
Barcelona- SPIN 
Neuropathological samples were obtained from the Neurological Tissue Bank of the 
Biobanc-HospitalClinic-IDIBAPS, and disease evaluation was performed according to 
international consensus criteria. Clinical samples were recruited from the multimodal Sant 
Pau Initiative on Neurodegeneration (SPIN) cohort (https://santpaumemoryunit.com/our-
research/spin-cohort/) 13, and were evaluated at the Memory Unit at Hospital de Sant Pau 
(Barcelona). The repository includes clinical data of more than 6,000 participants, >2900 
plasma samples, genetic material (DNA and RNA) of >3,200 and >400 subjects, 
respectively, and >2,000 CSF samples. All controls had normal cognitive scores in the 
formal neuropsychological evaluation and normal core CSF AD biomarkers, based on 
previously published cut-offs14. AD patients fulfilled clinical criteria of “probable AD 
dementia with evidence of the AD pathophysiological process”3 and therefore had 
abnormal core AD biomarkers (low Aβ1–42 and high t-Tau or p-Tau) in the CSF. The 
original protocol and the subsequent amendments were approved by our local Ethics 
Committee at the Sant Pau Research Institute as well as the Committee of the 
Neurological Tissue Bank. The SPIN cohort is based on blinded enrollment and only 
clinically relevant biomarker results are disclosed. 
100-plus Study 
The 100-plus Study, is a prospective cohort study of cognitively healthy centenarians that 
associated with the Alzheimer Center at the Amsterdam University Medical Center. 
Detailed participant recruitment and procedures were described previously15. Trained 
researchers visited the centenarians at their home residence annually, where they were 
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subjected to questionnaires regarding demographics, lifestyle, medical history, physical 
well-being and objective measurements of cognitive and physical functions. Cognitive 
function is tested by an extensive neuropsychological testing battery. Approximately 30% 
of the centenarians agreed to post mortem brain donation. For the current study, DNA 
samples 276 centenarians were included who completed at least one neuropsychological 
test at baseline, and exome sequencing from 254 centenarians passed QC (removal was 
mostly due to kinship). The 190 centenarians who scored >22 on the MMSE were 
regarded as controls, while 64 centenarians who scored <=22 were regarded as cases16. 
The Medical Ethics Committee of the Amsterdam UMC approved this study and informed 
consent was obtained from all participants. The study has been conducted in accordance 
with the declaration of Helsinki. All brain donors signed informed consent for brain 
donation. 
ERF 
The Erasmus Rucphen Family (ERF) study is a family-based cohort study that is 
embedded in the Genetic Research in Isolated Populations (GRIP) program in the South 
West of the Netherlands. The aim of this program was to identify genetic risk factors in 
the development of complex disorders. For the ERF study, 22 families that had at least 
five children baptized in the community church between 1850-1900 were identified with 
the help of genealogical records. All living descendants of these couples and their 
spouses were invited to take part in the study. Data collection started in June 2002 and 
was finished in February 2005. 
 
Rotterdam Study 
The Rotterdam Study is an ongoing prospective population-based cohort study, focused 
on chronic disabling conditions of the elderly 1, of which a random subset was exome 
sequenced. Participants were screened for dementia at baseline and at follow-up 
examinations using the Mini-Mental State Examination (MMSE) and the Geriatric Mental 
Schedule (GMS) organic level 2,3. Screen-positives (MMSE <26 or GMS organic level 
>0) underwent extensive examination 4. Finally, individuals were diagnosed in 
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accordance with standard criteria for dementia (Diagnostic and Statistical Manual of 
Mental Disorders, Third Edition, Revised (DSM-III-R)) and Alzheimer’s disease, NINCDS-
ADRDA 5. Follow-up for incident dementia was complete until January 1st, 2014. The 
Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus 
MC and by the Ministry of Health, Welfare and Sport of the Netherlands, implementing 
the Wet Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam Study). All 
participants provided written informed consent to participate in the study and to obtain 
information from their treating physicians. 
AC-EMC  
The Alzheimer Center Erasmus MC cohort (AC-EMC) includes patient referred to the 
Department of Neurology of the Erasmus Medical Center (Rotterdam, the Netherlands). 
DNA samples from 81 patients with probable AD were included in the current study. The 
average age at onset was 59 years (range 41-72). The majority of patients (64%) had a 
positive family history, defined as at least one first degree relative with dementia. All 
patients underwent clinical examination, neuropsychological assessment, neuroimaging, 
and if indicated, a lumbar puncture. The diagnosis was established according to the 
National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s 
Disease and Related Disorders Association (NINCDS-ADRDA) criteria for AD3.The study 
was approved by the Medical Ethical Committee of the Erasmus Medical Center, and 
written informed consent was obtained from all participants or their legal representatives. 
ADC-Amsterdam 
The ADC-Amsterdam cohort includes patients who visit the memory clinic of the 
Alzheimer Center at the Amsterdam University Medical Center, The Netherlands, and 
was described previously17. DNA samples from 518 patients with probable AD cases were 
included in the current study. Individuals in this cohort were extensively characterized to 
reduce the chance of misdiagnosis. Patients underwent an extensive standardized 
dementia assessment, including medical history, informant-based history, a physical 
examination, routine blood and CSF laboratory tests, neuropsychological testing, 
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electroencephalogram (EEG) and MRI of the brain. The diagnosis of probable AD was 
based on the clinical criteria formulated by the National Institute of Neurological and 
Communicative Disorders and Stroke—Alzheimer’s Disease and Related Disorders 
Association (NINCDS-ADRDA) and based on National Institute of Aging–Alzheimer 
association (NIA-AA). Clinical diagnosis is made in consensus-based, multidisciplinary 
meetings. All patients gave informed consent for biobanking and for the use of their 
clinical data for research purposes. Selection for whole exome sequencing was based on 
an early age-of-onset (age at diagnosis <70 years) and available CSF biomarkers. 
PERADES 
The PERADES sample (Defining Genetic, Polygenic and Environmental Risk for 
Alzheimer’s Disease) comprises individuals with Alzheimer’s disease (AD) and healthy 
controls recruited across UK, Italy and Spain. The majority of the individuals are from the 
UK (n=4095 with samples recruited in Cardiff: n=2405), while the rest (n=841) were 
recruited in Spain and Italy. More specifically the recruitment centres were: MRC Centre 
for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK; Institute of 
Psychiatry, London, UK; University of Cambridge, Cambridge, UK; University of 
Southampton, Southampton, UK; University of Nottingham, Nottingham, UK; Catholic 
University of Rome, Rome, Italy; Santa Lucia Foundation, Rome, Italy; Instituto di 
Neurologia Policlinico Universitario, Rome, Italy; University of Milan, Milan, Italy; 
Laboratory of Gene Therapy, San Giovanni Rotondo, Italy; University of Perugia, Perugia, 
Italy; University of Cantabria and IDIVAL, Santander, Spain and the Regional 
Neurogenetic Centre (CRN), ASP Catanzaro, Lamezia Terme, Italy. The collection of the 
samples within the MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff 
University was through national recruitment through multiple channels, including 
specialist NHS services and clinics, research registers and Join Dementia Research 
(JDR) platform. The participants were assessed at home or in research clinics along with 
an informant, usually a spouse, family member or close friend, who provided information 
about and on behalf of the individual with dementia. Established measures were used to 
ascertain the disease severity: Bristol activities of daily living (BADL), Clinical Dementia 
Rating scale (CDR), Neuropsychiatric Inventory (NPI) and Global Deterioration Scale 
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(GlDS). Individuals with dementia completed the Addenbrooke’s Cognitive Examination 
(ACE-r), Geriatric Depression Scale (GeDS) and National Adult Reading Test (NART) 
too. Control participants were recruited from GP surgeries and by means of self-referral 
(including existing studies and Joint Dementia Research platform).  For all other 
recruitment, all AD cases met criteria for either probable (NINCDS-ADRDA, DSM-IV) or 
definite (CERAD) AD. All elderly controls were screened for dementia using the Mini 
Mental State Examination (MMSE) or ADAS-cog, were determined to be free from 
dementia at neuropathological examination or had a Braak score of 2.5 or lower. Control 
samples were chosen to match case samples for age, gender, ethnicity and country of 
origin. Informed consent was obtained for all study participants, and the relevant 
independent ethical committees approved study protocols.  The whole exome sequencing 
(WES) was performed in-house at the MRC Centre for Neuropsychiatric Genetics and 
Genomics, Cardiff University. With the Nextera technology (Nextera Rapid Capture 
Exome v1.2), DNA was simultaneously fragmented and tagged with sequencing adapters 
in a single step. The enriched libraries were sequenced using the Illumina HiSeq 4000 
(Illumina, USA) as paired-end 75 base reads according to manufacturer’s protocols. 
 
CBC: Control Brain Consortium 
The Control Brain Consortium consists of 478 was previously described18. Whole-exome 
sequencing in 478 samples derived from several brain banks in the United Kingdom and 
the United States of America. Samples were included when subjects were, at death, over 
60 years of age, had no signs of neurological disease and were subjected to a 
neuropathological examination, which revealed no evidence of neurodegeneration. 
The data was made publicly available at www.alzforum.org/exomes/hex. 
 
 
UCL-DRC EOAD 
University College London Dementia Research Centre (UCL-DRC) early-onset 
Alzheimer’s disease cohort included patients seen at the Cognitive Disorders Clinics at 
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The National Hospital for Neurology and Neurosurgery (Queen Square), or affiliated 
hospitals. Individuals were assessed clinically and diagnosed as having probable 
Alzheimer’s disease based on contemporary clinical criteria in use at the time, including 
imaging and neuropsychological testing where appropriate. All individuals consented for 
genetic testing and had causative mutations for Alzheimer’s disease (PSEN1, PSEN2, 
APP) and prion disease (PRNP) excluded prior to entry into this study. 
ADSP 
Cases and controls were selected from over 30,000 non-Hispanic Caucasian subjects 
from multiple cohorts described in detail elsewhere19.   All controls were greater than 60 
years and were cognitively normal based on direct assessment.  All cases met NINCDS-
ADRDA criteria for possible, probably, or definite Alzheimer’s disease. All cases had a 
documented age-at-onset, and for those with pathologically conformed AD, an age-at 
death.   APOE genotypes were available for all.  Cases were selected to have a minimal 
AD risk based on sex, age and APOE genotype.  Controls were selected as those with 
the least probability of converting to AD by age 85.  Controls were older (86.1 years, SD 
= 5.2) that cases (76.0 years, SD = 9.2).  The selection criteria and the rationale for study 
design are described elsewhere20. We selected 5,096 cases and 4c,965 controls for 
exome sequencing by this protocol.  In addition, we selected 682 additional cases from 
multiplex families with a strong AD family history.  Because some of these subjects were 
Caribbean Hispanics, we also sequenced 171 cognitively normal Caribbean Hispanic 
controls.   
 
Alignment and variant calling 
Raw sequencing data from all studies were collected on a single site (Cartesius 
Supercomputer provided by SURF, in the Netherlands), and processed with a uniform 
pipeline. Reads were extracted from FastQ, BAM, CRAM or SRA files. For each lane/read 
group separately, paired reads were converted to SAM format using FastQToSam or 
picard RevertSam (Picard Tools version 2.10.521), processed with Picard 
MarkIlluminaAdapters and subsequently transformed to interleaved fastq format with 
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Picard SamToFastq (while setting marked adapter regions to base quality 2). Next, reads 
were aligned to the human reference genome (build 37 with decoys) using the BWA MEM 
algorithm (BWA version 0.7.15-r1140)22. Alignments were processed with Samblaster 
(version 0.1.24) to add mate tags23. Read group alignments were then merged and 
duplicate reads were marked using Picard MarkDuplicates.  We found that the presence 
of novel Indels and novel SNPs in certain samples correlated with the presence of larger 
amounts of soft-clipped reads, indicative of the presence of chimeric DNA fragments. 
Each sample for which the percentage of soft-clipped base alignments exceeded 0.5% 
was therefore processed with a custom tool (see below) which identified and removed 
parts of reads that were likely of chimeric origin. This tool was executed after the Picard 
MarkDuplicates step. Then, reads were sorted to chromosome order by samtools sort 
(version 1.8)24. We estimated contamination percentages using VerifyBamID225, 
retrieved 4 September 2018), while correcting for the 2 PCA components (default), and 
excluding common SNPs (allele frequency ≥0.01) present in the 1000-genomes dataset 
(phase3, version 5b)26. Base quality scores were recalibrated using GATK BQSR (version 
3.8-1)27. on the sample capture kit region + 100bp padding. Known indels were obtained 
from the Mills and 1000G gold standard indels in the GATK resource kit27. Known SNPs 
were obtained from dbSNP (version 150) and gnomAD (version 2.0.2)28. Subsequently, 
variants were called on the sample capture kit region + 100bp padding using the 
HaplotypeCaller27, while using the ‘-contamination’ correction option, with the estimated 
contamination percentages. Ploidy was set to 1 for chromosome Y, and 2 for the other 
chromosomes, minPruning was set to 2, and the new quality model (--newqual) was used. 
Results were exported as gVCF format. Finally, gVCFs were combined per study in 
batches with a maximum size of 500 samples using GATK CombineGVCF. Then, variants 
were called using GATK GenotypeGVCF29, using the new quality model and setting max-
alternate-alleles to 20. Variants were then annotated with GATK variant score recalibrator 
(VQSR) using allele specific annotations, while for all other options the best practices 
were followed. 
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Chimeric read declipping 
Chimeric fragments consist of multiple genomic sequences, joined together into one 
sequence. Sequencing of such fragments can result in reads that do not entirely align to 
the genome, and/or align at multiple locations. This results in so-called ‘soft-clipped’ 
alignments, where parts of the read sequence are not aligned. These soft-clipped regions 
cause issues for the variant caller, as it uses not just the aligned part of the reads, but 
also the unaligned soft-clipped regions during local reassembly and variant calling. The 
reason for this is that these clipped sequences can be an indication of an insertion variant. 
In case these clipped regions are caused by chimera’s, this is however not a correct 
strategy, and can cause false variant calls. To prevent their effect on variant calling, we 
i) estimate the extent of the chimera problem by quantifying the number of soft-clipped 
alignments, and ii) remove these soft-clipped sections for affected samples if they are 
(likely) caused by chimeras. To do this, the soft-clipped sections are turned into hard-
clipped alignments, in which the underlying sequence is removed (the read is shortened), 
such that the variant caller cannot revive the clipped sequence during variant calling. In 
the following description, we assume paired end sequencing (in which both ends of the 
fragment are sequenced, resulting in two reads). We remove the following soft-clipped 
sequences: 
i) One well-known type of artificial chimera occurs when the sequenced fragment is 
shorter than the read length. Fragments have adapters at the end, used as starting point 
for sequencing. In these cases, the 3’ end of read 1 will cover the adapter of read 2, and 
vice versa. Due to this, read 1 and 2 will have overlapping alignments with possibly soft-
clipped 3’ends. Such read pairs can be detected based on their overlapping alignments. 
To remove the adapter sequence, we align the known adapter sequence to determine the 
clipping point, and hard-clip the identified sequences from there.  
ii) A genomic chimera can have a join-point at different sites in the sequence fragment.  
— If the chimeric join point occurs between read 1 and 2, or close to the end of read 1 or 
2, then read 1 and 2 will (usually) be aligned at a distance from each other. If this 
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distance is >100kb, or one of the reads is unmapped, we remove the soft-clipped 
regions at the 3’end of both reads.  
— If there are multiple, mostly non-overlapping, alignments for a read at different 
genomic locations, it is usually an indication that the chimeric join point occurs 
somewhere in the middle of that read.  The overlapping parts of these alignments are 
pruned (in all alignments for that read). Then, soft-clipped sequences in the 
alignments that face each other are hard-clipped. 
— in the above situation, it frequently occurs also that the fragment is short. The chimeric 
join point might then be present in both reads. If both reads have multiple alignments, 
we handle each read as described above.  
— if the fragment is short, but not very short, read 1 might have multiple alignments, 
while read 2 has a soft-clipped 3’end (or vice versa).  For example, for genomic region 
A and B, a chimeric fragment might read AABBB.  Read 1 (AABB) might then have 
multiple alignments, one for the AA and one for the BB section.  Read 2 (BBBA) 
however might have only an alignment for B, but not for A, as the sequence from A is 
too short to obtain an accurate alignment. The chimeric sequence A in read 2 will 
therefore be soft-clipped. We detect these situations based on overlapping alignments 
for fragment B, and hard-clip the soft-clipped 3’end of read 2. 
— if the chimeric sequence consists of a very short piece at the 5’ end of either read 1 
or 2, this part might not be aligned as it is too short. It is in these situations unclear if 
the sequence has a chimeric origin, as such unaligned pieces can also be caused by 
indels. We find that in samples affected by chimeras, it is beneficial to remove these 
soft-clipped 5’ends. While this reduces the coverage of indels, in most cases many 
fragments still cover the complete indel. Also, differences in coverage between 
samples occurs commonly in exomes, where the covered regions are highly variable 
between capture kits, and handling this is part of the downstream pipeline (see 
posterior probabilities).  
— After removal of the soft-clipped regions caused by chimera’s, we unalign the 
alignments that are <= 1bp in length, we transform supplementary alignments to 
primary alignments if the primary alignment is unaligned, drop unaligned 
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supplementary alignments, update alignment tags, and validate the read records and 
cigar strings.  
Sample QC 
Before sample QC, we performed a pre-variant QC step, to remove bad quality variants 
(see Variant QC steps for details) that might impact sample quality statistics. In addition, 
we required that at least 25% of the samples had to have at least read depth 6. Next, 
sample QC was performed according to the steps described in Figure 1a, which are 
detailed below.  
1. Missingness 
We removed samples that had a contamination over 0.75, or a GQ<20 for 60% of the 
variants in its own exome kit, or a depth < 6 for 65% of the variants in its own exome kit. 
Additionally, we removed samples for which chromosomes were missing (GQ < 20 for 
99% of the variants on a chromosome in the samples exome kit).  
2. Contamination 
Samples with a contamination percentage > 7.5% were removed. 
3. Sex-check 
We performed a sex-check, by comparing annotated sex with genetic sex (Figure S5). 
Genetic sex was determined based on the coverage of the sex chromosomes. Coverage 
was determined using off-target reads. Only coverage in regions outside capture kits 
(+500 bp padding), outside peaks in coverage called with MACS (version 1.4)30 and 
outside segmental duplications (Segmental Dups track downloaded from UCSC which 
includes the PAR regions31. Coverage was determined in 20kb windows, and normalized 
for GC content using linear regression. Regions of 20kb with more than 100 N bases were 
discarded. X and Y chromosome coverage was normalized by dividing by the autosome 
coverage. Thresholds were set empirically, based on the distribution of male and female 
samples (see supplemental figure).  
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4. Population outliers 
Next, we performed a PCA analysis to identify population outliers. Variants that were in 
the intersection region of all capture kits, and had a minor allele frequency ≥0.005 and a 
depth ≥6 for 90% of the variants, were used for this purpose. Variants were pruned with 
bcftools +prune tool (version 1.8)24 with max LD set to 0.2 in 500kb windows. Only 
variants that were also in the 1000 genomes dataset (phase 3, v5b) were kept. PCA was 
performed on dosages (based on genotype calls for 1000G, and based on genotype 
probabilities for the study samples). Variant dosages were first normalized, as 
described32, based on statistics obtained on the 1000G samples. Then, PCA was 
performed on the 1000G samples, and all ADES samples were mapped to this PCA space 
(Figure S6). Finally, we removed outliers for each of the first 4 PCA components (Figure 
S7, Figure S8), where outliers were defined as samples that fell outside the range 
median(pca_component) ± 8 * mad(pca_component), where mad is the median absolute 
deviation and the pca_component vector only contains the ADES samples.  
5,6: Excess novel SNPs or indels 
We calculated and compared the number of novel SNPs and the number of novel indels 
per study, both in the union of the capture kits (Figure S9 and Figure S10) and the 
intersection of the capture kits (Figure S11, Figure S12). Novel variants were defined 
as variants that were not present in DBSNP v150. These statistics were calculated 
based on posterior dosages (described below). Thresholds were set at the median 
value + 6 * mad for novel SNPs and +12*mad for novel Indels.  
7. Het/hom and TsTV 
Furthermore, we performed a per-sample QC on the following statistics (calculated on the 
intersection of the capture kits): Ts/Tv ratio of known variants (Figure S13), and Ts/Tv 
ratio of novel variants (Figure S14), Het/Hom rate of known SNPs (Figure S15). The 
acceptable range for Het/Hom was set to ±6 * mad. For Ts/tv measures, only a lower limit 
of -6 * mad was used.  
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8. IBD analysis 
We performed an IBD analysis on the remaining samples using Seekin33. We kept 
variants with a minor allele frequency ≥0.005, and for which at least 90% of the samples 
had depth >=6. Variants were pruned with bcftools +prune tool (version 1.8), with max LD 
set to 0.2 in 500kb windows. Only variants that were also in the 1000G dataset were kept. 
We performed a PCA as described before. Using Seekin (version 1.0), we corrected for 
these PCA components using the options ‘modelAF’ and ‘getAF’, using 4 PCA 
components. Next, kinship was determined using all variants with the heterogeneous 
estimator of Seekin33. Duplicate samples with inconsistent annotation were removed 
(inconsistent status, APOE genotype, or gender, or more than 2 years difference in age 
at onset for cases). Otherwise, we kept the sample with the most complete annotation: 
we preferred samples with age (at onset), and APOE genotype over samples without. 
Also, we preferred whole genome sequenced samples over exomes, and samples with 
lower missingness over samples with higher missingness. For related samples up to 3rd 
degree (marked by the threshold of >9.4% shared identity by descent, which is the middle 
value between the expected value for 3rd-degree (12.5%) and 4th-degree (6.25%)), we 
preferred (in order) cases over controls, samples with more clinical data (age (at onset), 
apoe status), WGS samples, and samples with higher coverage.  
9. Bad PCR plates 
We removed all samples on 3 PCR plates that were enriched with gender mismatches.  
10. Removal of Mendelian AD-related variant-carriers 
Next, we performed a manual curation of causative variants in a short list of Mendelian 
dementia genes. We extracted rare variants in the following two gene lists and interpreted 
them following the American College of Medical Genetics and Genomics and the 
Association for medical Pathology34, (i) autosomal dominant AD genes: APP, PSEN1, 
PSEN2 (autosomal dominant AD), GRN, MAPT, FUS, TARDBP, VCP, (fronto-temporal 
lobar degeneration spectrum), NOTCH3 (CADASIL), PRNP (Prion diseases); (ii) 
autosomal recessive genes: NPC1, NPC2 (Niemann-Pick type C disease), TYROBP, 
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TREM2 (homozygous LOF: Nasu-Hakola disease, 1 carrier)). Carriers of variants that 
reached enough evidence to be rated at least as likely pathogenic (class 4) were excluded 
from the analysis, whatever their disease status. Of note, for autosomal recessive genes, 
heterozygous carriers were not excluded, only carriers of bi-allelic pathogenic variants 
were excluded. 
11. AD label 
We excluded samples for which clinical information was indicative of non-AD dementia 
(e.g. vascular dementia). In addition, part of the case-control sample included minimal 
neuropathological information. Among them, we further excluded samples with discordant 
Braak stages, i.e. cases with stage <2 (n=265) and controls with stage >4 (n=43). Finally, 
21,345 samples were available for analysis, constituting 12,652 cases (of which 4060 had 
early onset AD, onset ≤ 65 years) and 8693 controls. 
Variant QC 
Throughout an extensive QC, we attempted to find root causes for the presence of false 
variants. We identified two significant issues that were not handled by the default variant 
calling pipeline. After removal of samples excluded by the sample QC, variant statistics 
were recalculated. Then, we performed variant QC as described in (Figure 1B). 
1a. Multi allelic variants 
First, multi-allelic variants were split into bi-allelic variants, and indels were normalized, 
using the bcftools norm tool. The tool was modified to also split the phased PGT fields, 
such that downstream variant merging was possible. Additionally, the splitting of the 
genotype likelihoods and read counts was modified (PL and AD fields), which is detailed 
in the next section. We removed bi-allelic variants that had as alternate allele ‘*’ (which 
reflects overlap with a deletion variant), as well as multi-allelic variants for which the 
reference allele was lower in frequency than the frequency for at least two alternate 
alleles. 
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1b. Variant merging  
Variants that were in close vicinity, in cis and always occurred together, were merged into 
single events, to account for for example nearby frameshifts that cancel each other out. 
Only indels with ≤10bp distance and snps with ≤2bp distance were considered for 
merging. We used the read-phasing output of GATK (PID/PGT) fields to determine which 
variants occurred in-phase. 
2. Oxo-G  
In some samples novel variants were enriched for G>T and C>A variants, caused by the 
oxygenation of G bases during sample processing35. Using a custom tool (see below), 
that uses per-sample statistics from Picard CollectSequencingArtifactMetrics, we 
identified and filtered variants and variant calls that could be attributed to this issue. We 
removed variants with an average OXO sensitivity > 1.5, or a remaining total dosage after 
OXO correction ≤0.1.  
3. STR/LCR regions 
STR and LCR regions were obtained respectively from the simple tandem repeats track 
by TRF from UCSC, and the LCRs as identified by the mdust program36. Variants in these 
regions were excluded. 
4. Allele Balance 
The balance between reference and alternate reads (allele balance) was determined both 
for heterozygous and homozygous calls. Allele balance was calculated based on 
posterior genotype probabilities (see below).  Variants that had an average allele balance 
< 0.25 or > 0.75 for heterozygous calls, or < 0.9 for homozygous calls were removed.  
5. Depth Fraction 
The relative depth of heterozygous calls to other calls was determine, based on posterior 
genotype probabilities (see below). Variants for which the heterozygous depth was < 20% 
of the depth of other calls were removed. 
 44 
6. Hardy Weinberg 
Hardy-Weinberg scores (all samples and control samples: hw_all and hw_control) were 
calculated based on posterior genotype probabilities (see below).  We removed variants 
for which the p-value for control samples was < 5 * 10-8. 
7. VQSR  
Variants that were tagged by the variant quality score recalibration method from GATK 
were removed, for SNPs we removed variants from the VQSR > 99.5% tranche, while for 
indels we removed variants from the VQSR > 99.0% tranche. 
Pre-variant QC versus final variant QC 
For the pre-variant QC, which is performed prior to performing the sample QC, we 
performed all the above steps. Additionally, we removed variants with a missingness rate 
> 25%. Genotype calls which had a depth < 6 were considered missing. For the final 
variant QC, the missingness step was not performed, as it is included as part of the variant 
selection. Compared to the pre-variant QC, the final variant QC had variant batch 
detection as an additional step.  
8. Variant Batch Detection 
Finally, we developed a custom tool to remove variants that still presented batch effects 
that were not explainable by population structure or phenotype effects (see below). On 
variants identified to have a batch effect, we attempted variant batch correction, by setting 
batches that caused problems for a certain variant to missing. Afterwards, variants that 
still had a VBD score > 25, or a VBD score > 15 and MAF < 0.005 were removed from 
the analysis.  
Genotype posterior probabilities 
Due to the use of different capture kits and whole genome sequencing (WGS) data, the 
analysed dataset has highly variable coverage patterns across the samples. Many 
variants have as a consequence less than 100% coverage across the samples. In burden 
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testing, a missingness percentage of up to 20% is allowed. This requires an accurate 
handling of missing genotype calls in variants that contribute to the burden score.  In 
cases of low and absent read coverage, direct calling of the genotype is not possible. 
Therefore instead, a probabilistic approach is used, in which each genotype is assigned 
a certain probability. 
Genotype likelihoods  
The GATK variant caller outputs the likelihood of each sample genotype in the PL field of 
the VCF. These likelihoods are based on the available sequencing reads for a sample. In 
case of missing data, each genotype is considered equally likely (i.e. p=⅓ in case of 
diploid chromosomes for ref/ref, ref/alt and alt/alt genotypes). These likelihoods cannot 
be used directly in a burden analysis, as by assuming equal likelihoods for each genotype 
the allele frequency of samples with missing coverage would effectively by 50%, and likely 
substantially differ from that of samples with coverage.  
Posterior probability  
This is solved by the use of posterior probabilities. Here the allele frequency in the study 
sample is used as a prior in assigning genotype probabilities. Using Bayes theorem, 
posterior genotype probabilities take the following form (assuming a diploid setting): 
𝑃(𝑔) =
𝐿(𝑔) 𝜓(𝑔) 
∑ 𝐿(𝑖)∗𝜓(𝑖)𝐺𝑖
, where P(g) is the posterior probability for genotype g, with g encoded 
as 0,1 or 2 for respectively the reference, heterozygous and homozygous alternate 
genotype. L(g) is the genotype likelihood as given by the variant caller. The genotype 
frequency 𝜓(𝑔) =
2
(2−𝑔)!𝑔!
𝜔𝑔(1 − 𝜔)2−𝑔is derived from the allele frequency 𝜔, assuming 
Hardy-Weinberg equilibrium. Notably, the allele frequency 𝜔 needs to be derived from 
the study sample, such that 𝜔  matches the allele frequency in samples with coverage, 
thereby preventing biases. A difficulty is that accurate estimation of this allele frequency 
requires posterior genotype probabilities. Here we follow the approach previously 
described by Li et al37 using an EM-algorithm in which iteratively posterior probabilities 
and the allele frequency are estimated, until convergence (maximum difference in allele 
 46 
frequency between iterations is 1e-7) is reached. Finally, posterior dosages in the diploid 
case were calculated as d = P(1) + 2 P(2).  
Multi-allelic variants  
As described in the previous section, variants with multiple alleles are split into bi-allelic 
variants prior to analysis. For this, the bcftools norm tool is used. However, splitting of the 
genotype likelihood was adapted from the default approach in bcftools. The standard 
REF/ALT interpretation of the resulting biallelic likelihoods was considered problematic 
for the analysis, as often the alleles would be neither REF nor ALT. Genotype probabilities 
would then not sum to 1. We adapted therefore to a NON_ALT/ALT interpretation of bi-
allelic variants. Specifically, this meant that genotype likelihoods were converted to 
probabilities, and then summed to obtain the NON_ALT/NON_ALT, NON_ALT/ALT and 
ALT/ALT genotype probabilities (separately for each ALT in the multi-allelic variant to 
create multiple bi-allelic variants). Notably, in the absence of coverage, the variant caller 
considers each multi-allelic genotype equally likely. In this situation, the 
NON_ALT/NON_ALT genotype becomes the most likely genotype, as it sums more 
genotypes. As this causes biases, we correct for this, using an additional prior equal to 1 
/ (#summed multi-allelic genotypes) for each bi-allelic genotype.  Next to the genotype 
likelihood, the read count field (AD field) was also modified to follow the above described 
NON_ALT/ALT interpretation. To that end, read counts that contributed to the  
NON_ALT/NON_ALT and NON_ALT/ALT genotypes were summed during variant 
splitting.  
Posterior sample QC-measures  
Standard sample QC measures, when calculated on variant calls, are affected by 
samples with low or missing coverage.  To prevent that, these measures were instead 
based on genotype posterior probabilities: 
— Nr. of indels/SNPs:  Determined by summing (across all samples) posterior dosages.  
— Ts/Tv ratio: Determined by summing posterior dosages of transition variants and 
dividing them by the summer posterior dosages of transversion variants 
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— Het/Hom ratio: Determined by summing (across all samples) the posterior genotype 
probability of the heterozygous genotype, and dividing it by the summed posterior 
genotype probability of the homozygous genotype.  
Posterior variant QC-measures 
— Heterozygous allele balance:  Defined as 
∑ 𝑃𝑖(1) 𝑟𝑟𝑒𝑓
𝑁
𝑖
∑ 𝑃𝑖(1) (𝑟𝑟𝑒𝑓+𝑟𝑎𝑙𝑡)
𝑁
𝑖
 , where Pi(1) is the 
posterior genotype probability for the heterozygous genotype for sample i, N is the 
number of samples, and rref and ralt are the number of reads carrying the reference or 
alternate genotype.  
— Homozygous allele balance: Defined as 
∑ 𝑃𝑖(2) 𝑟𝑎𝑙𝑡
𝑁
𝑖
∑ 𝑃𝑖(2) (𝑟𝑟𝑒𝑓+𝑟𝑎𝑙𝑡)
𝑁
𝑖
, where Pi(2) is the posterior 
genotype probability of the homozygous genotype for sample i.  
— Heterozygous depth ratio:  Defined as 
∑ 𝑃𝑖(1) (𝑟𝑟𝑒𝑓+𝑟𝑎𝑙𝑡)
𝑁
𝑖
∑ 𝑃𝑖(1)
𝑁
𝑖
(𝑟𝑟𝑒𝑓+𝑟𝑎𝑙𝑡)/𝑁
. 
— Hardy-Weinberg equilibrium: Posterior genotype probabilities assume Hardy-
Weinberg equilibrium (HWE), thereby biasing variants with high rates of missingness 
towards HWE. Hardy-Weinberg equilibrium is therefore tested on non-probabilistic 
genotype calls, after filtering out samples with a read coverage < 6. 
Oxo-G variant call filtering 
During sample preparation, oxidation of G-nucleotides can lead to the generation of 8-
oxoguanine lesions in DNA. These lesions lead to false positive G-T variants, and, 
dependent on the protocol step in which the oxidation occurs, also false positive C-A 
variants35. While this is primarily an issue for somatic variant calling, it also impacts 
germline rare-variant calls, in particular in exomes where coverage is variable. In modern 
protocols, these effects have mostly been mitigated, however, in older samples these 
false positive mutations can be a significant source of errors.  Next to oxoG errors, similar 
problems are known to occur in DNA obtained from formalin-fixed samples. In these 
samples, deamination can occur, converting cytosine to uracil (C>U), thereby creating 
false positive C->T (and G->A) mutations. While the approach below handles these types 
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of errors as well, this problem was not encountered in a significant manner in the dataset. 
A modern variant caller such as GATK determines nucleotide-specific base error rates 
based on a comparison of the sequenced reads to the genome (in the case of GATK 
through base quality score recalibration (BQSR)). In GATK, this error rate is modelled on 
the observed nucleotide in the read (e.g. in case of a G->T mutation a T for reads aligned 
to the positive strand and an A for reads aligned on the negative strand). Although G-
oxidation will lead to a somewhat higher base error rates in T and A nucleotides, the 
variant caller does not recognize that these errors occur mainly when the genomic 
reference contains respectively a G  (or C in case of C->A mutations). This leads to 
underestimated error rates and, in the end, false positive variant calls. Briefly, our 
approach to detect and filter these oxo-G affected variant calls is therefore based on 
comparing i) the dosage as determined when considering a error model that does not 
consider oxoG errors   ii) the dosage as determined with a model that does consider 
(sample-specific) oxoG errors. The ratio of these two dosages is considered a ‘sensitivity’ 
score, which is used to filter genotype calls and/or variants.  Dosages are computed using 
a genotype likelihood calculation detailed below, and are ‘posterior dosages’ (see 
previous section): continuous numbers between 0 and 2, which take into account the 
confidence in the genotypes and the frequency of the variant in the study sample. In the 
variant QC pipeline, genotype calls with a sensitivity > 1.5 are set to missing, after which 
variant QC statistics are recalculated. Variants are flagged for exclusion if they have an 
average sensitivity > 1.5 or a summed dosage with the oxo-G error model < 0.1.  The 
average sensitivity of a variant is here defined as the ratio of the summed normal dosages 
and the summed oxo-G-corrected dosages. In more detail, the method consists of the 
following steps: 
 
Statistics  
To determine the parameters for the base error model, we estimate for each sample the 
rate at which oxidation and other base errors occur, dependent also on different sequence 
contexts (neighboring bases affect the G-oxidation rates). These per-sample statistics are 
collected using Picard CollectSequencingArtifactMetrics. Next to base errors, we also 
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obtain summary error metrics per sample, based on measures available as part of the 
CollectSequencingArtifactMetrics. These consider two forms of the oxoG errors: pre-
adapter  (in this case G->T errors occur in forward reads, and C->A errors in backward 
reads) and bait-bias (in this case G->T errors occur in the exome template strand (often 
the positive strand), and C-A errors in the reverse strand).   
Full error model  
The error model describes mutation-specific error rates (in contrast to the usual read-
nucleotide specific error rates). It takes into account sequence context (a single 
nucleotide before and after the variant). Strand-specific and forward/backward read 
specific error rates are averaged: although this information would be useful, it is not 
available per sample in the variant file (VCF), and a direct link between the original reads 
in the bam file and the read count in the VCF file is not straightforward to make due to the 
reassembly step performed by the variant caller.  
Contrasting error model   
A contrasting error model is created which exclusively models non-oxoG related errors. 
To this end, we select samples that are not affected by oxoG-related issues, based on 
the previously described summary metrics. As these summary metrics are sequence-
context specific, we obtain a worst-case summary metric per sample, by taking the 
highest error value across all sequence contexts per sample. Samples with an error rate 
> 0.0001 for either pre-adapter or bait-bias errors are excluded. Using the remaining 
samples, regression models are trained which predicts (sequence context-specific) G->T 
and C->A mutation rates. These regression models are used to fill in G->T and C->A 
mutation rates for the samples that were excluded due to oxoG effects.  Features for 
these regression models are the (sequence-context-specific) mutation rates for all 
mutations except G->T and C->A. To handle the extensive collinearity in these features, 
we reduce the feature space to 10 dimensions by using PCA, and make use of ridge 
regression.  
 50 
Genotype likelihood calculation  
For each sample, genotype likelihoods are calculated both using the contrasting and full 
error model. Read counts (rref and ralt for respectively reads carrying the reference and 
the alternate allele) are obtained from the VCF file. Based on the error model, sequence 
context, and reference and alternate allele, ref->alt (era) and alt->ref (ear) error rates are 
obtained. For a sample s (identifier omitted for brevity), and assuming a diploid setting, 
the likelihood of each genotype is calculated then as: 
ref/ref:  (1 − 𝑒𝑟𝑎)
𝑟𝑟𝑒𝑓 + 𝑒𝑟𝑎
𝑟𝑎𝑙𝑡 
ref/alt:   (
(1−𝑒𝑟𝑎) + 𝑒𝑎𝑟
2
)
𝑟𝑟𝑒𝑓
+ (
(1−𝑒𝑎𝑟) + 𝑒𝑟𝑎
2
)
𝑟𝑎𝑙𝑡
 
alt/alt:  (1 −  𝑒𝑎𝑟)
𝑟𝑎𝑙𝑡 + 𝑒𝑎𝑟
𝑟𝑟𝑒𝑓 
 
Likelihoods are normalized to sum to 1, and then converted to posterior probabilities 
( 𝑝𝑟𝑒𝑓/𝑟𝑒𝑓, 𝑝𝑟𝑒𝑓/𝑎𝑙𝑡 and 𝑝𝑎𝑙𝑡/𝑎𝑙𝑡) as outlined in the previous section.  The dosage per sample 
is then calculated as 𝑑𝑠 = 𝑝𝑟𝑒𝑓/𝑎𝑙𝑡,𝑠 + 2 𝑝𝑎𝑙𝑡/𝑎𝑙𝑡,𝑠 (where s refers to a specific sample) while 
sensitivity per sample is  determined as: 𝑠𝑠 = 𝑑𝑐𝑜𝑛𝑡𝑟𝑎𝑠𝑡𝑖𝑛𝑔,𝑠/𝑑𝑓𝑢𝑙𝑙,𝑠. Here, full and 
contrasting refer to the used error model to calculate the dosage. In practical use, we 
found that estimated oxoG-related errors are underestimated. This can be attributed to 
two factors: i) information loss as no information on read strand, and presence of 
mutations on forward and backward reads could be used. This could have diluted the 
estimated oxoG related-errors by a factor 2, ii) a selection bias, as false positive variants 
caused by this issue are likely sites that present more extreme oxoG-related errors, either 
by chance or due to (possibly unmodelled) sequence characteristics. To alleviate this 
issue, an error multiplication factor f was introduced, such that errors considered in the 
full model are rescaled according to 𝑓 (𝑒𝑓𝑢𝑙𝑙 − 𝑒𝑐𝑜𝑛𝑡𝑟𝑎𝑠𝑡𝑖𝑛𝑔) + 𝑒𝑐𝑜𝑛𝑡𝑟𝑎𝑠𝑡𝑖𝑛𝑔.  In practice, 
using 𝑓 = 5led to an adequate filtering of oxoG related variants.  
Genotype and variant filtering  
Next to a genotype sensitivity measure, we also calculate a variant sensitivity measure: 
𝑠𝑣𝑎𝑟𝑖𝑎𝑛𝑡 =
∑ 𝑑𝑐𝑜𝑛𝑡𝑟𝑎𝑠𝑖𝑛𝑔,𝑠𝑎𝑚𝑝𝑙𝑒
 
𝑠𝑎𝑚𝑝𝑙𝑒𝑠
∑ 𝑑𝑓𝑢𝑙𝑙,𝑠𝑎𝑚𝑝𝑙𝑒
 
𝑠𝑎𝑚𝑝𝑙𝑒𝑠
. Variants were exluded from the analysis if 𝑠𝑣𝑎𝑟𝑖𝑎𝑛𝑡 > 1.5, 
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or if ∑ 𝑑𝑓𝑢𝑙𝑙,𝑠𝑎𝑚𝑝𝑙𝑒
 
𝑠𝑎𝑚𝑝𝑙𝑒𝑠 < 0.1.  For variants with 𝑠𝑣𝑎𝑟𝑖𝑎𝑛𝑡 > 1.1 we performed genotype 
filtering, setting to missing all genotypes where the genotype sensitivity 𝑠𝑠 > 1.5. 
Afterwards, variant QC measures (missingness, Hardy-Weinberg, allele balance, etc) are 
recalculated.  
Variant batch detection and correction 
For genetic studies, statistical power is a primary concern. This necessitates large-scale 
collaborations between sites, as well as the collection of samples that have been 
sequenced across a large time period. In such settings, it is often impossible to control 
which capture kits are used, if exome or WGS sequencing is performed, and many other 
relevant sequencing parameters such as read or fragment lengths. In the ADES 
consortium, this has resulted in the use of 17 different (versions of) capture kits, the use 
of both exome and WGS sequencing, read lengths that vary from 50 to 150 bp (Figure 
S3), and many other differences. Moreover, the different contributing studies also have 
very different case/control balances, ranging from exclusively cases to almost exclusively 
controls. When performing variant association, this presents a problem, as this step is 
highly sensitive to batch effects. Even after sample and variant QC, we found that certain 
variants still present batch effects that lead to spurious associations. 
Examples of batch effects 
It is not always immediately clear what the cause of such remaining batch effects is. Some 
examples which were encountered: 
— Certain capture kit methods use restriction enzymes to cut sequence fragments before 
sequencing. We observe that mutations in these restriction sites can at some loci lead 
to an artificial loss of heterozygosity in the sequencing reads, resulting in a lower than 
expected allele frequency.  Additionally, it is not possible to filter out PCR duplicates 
for these kits, leading to possible false positive mutations.  
— For capture kits that fragment DNA at relatively ‘fixed’ positions in the genome we also 
observe an increase in batch effects. Explanations for this might include position-
related biases in reads or mutations that affect the read coverage of one haplotype. 
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This is observed for capture kits that use restriction enzymes for fragmentation, but to 
a lesser extent also for those that use transposases, which can have tagmentation 
biases38. Finally, such batch effects are also present in probe-based kits for variants 
that in terms of read length are distant from a capture probe. 
— Increased batch effects are also observed in WGS samples when compared to exome 
samples. A possible explanation might be that WGS samples have sequence reads 
originating from the whole genome, in contrast to exome capture kits.  In some cases, 
this could result in sequences being misaligned at certain locations that are not 
present when using (certain) exome capture kits.  
While not every batch effect can be easily be predicted based on causal mechanisms, 
the presence of many different batches in the dataset still enables the detection of these 
variants.  
Algorithm overview 
To this end, a method was developed to detect variants that are affected by such batch 
effects. The main challenge is to distinguish between non-technical effects that present 
as batch effects (such as a variant that is enriched in a certain country, and/or only in AD 
cases) and real batch effects that are caused by technical issues. This is solved by using 
a two-step approach. In the first step, the algorithm attempts to explain the presence of a 
variant in specific carriers only through population structure, presence of haploblocks, 
and/or phenotype effects. Secondly, it is determined if the explanation for the presence 
of a variant in specific carriers significantly improves if also technical covariates 
(membership of study batches, various sequencing parameters, etc.) are allowed.  
Variants for which this is the case are considered to be affected by technical issues, and 
are either corrected (detailed below) or not considered in the analysis. Below, we first 
detail the covariates that are used, the algorithm that is used to select the covariates, the 
regression model, how the presence of not-at-random missing genotypes (i.e. 
missingness depends on having a specific genotype) is detected, and finally how the 
algorithm is used in practice.  
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Technical covariates  
Statistics were generated with samtools24, Picard21, verifybamid225, and custom scripts. 
Covariates (which are vectors that contain for each sample a value) were defined for the 
following properties: 
— Batch, study, capture kit: Covariates describing (for each sample) membership (no: 
0, yes: 1) for each batch, study or (version of a) capture kit. 
— Read length, insert size:  Covariates describing read length and average fragment 
insert size. In addition, covariates were added describing the distance to the nearest 
capture probe (which differs across the samples due to the use of different kits), both 
in absolute terms, as well as relative to fragment size or read length (Figure S3). For 
WGS samples, 0 was used as the distance.  
— Contamination: Contamination percentage as determined by Verifybamid2 (see 
sample QC). 
— Missingness: Sample missingness (defined as genotype quality GQ < 40, for variants 
that are in the intersection of all capture kits, Figure S4) 
— Size selection: The standard deviation of fragment insert-sizes divided by the 
average of fragment insert sizes. Indicative of the extent of size selection that was 
performed on the fragments.  
— Read error rate: Error rate of the reads (mismatches / bases mapped).  
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— GC ratio: Depth of sequences with 35% GC / Depth of sequences with 50% GC 
— Mismapping ratio: Fraction of fragments for which the two reads map to different 
chromosomes 
— Duplicate ratio: Fraction of duplicated reads. 
— Not mapped ratio: Fraction of reads that are not mapped. 
— Read quality variability: Standard deviation of average Illumina quality scores across 
read cycles (a cycle corresponds to a single base position in each read). 
— Fraction of N nucleotides: Percentage of bases being the N (unknown) nucleotide. 
— Insertion/deletion error fraction: Nr. of insertions or deletions divided by the nr. of 
bases mapped. 
— Ts/tv rate, Het/Hom rate, Novel SNPs/Indels rate:  Sample statistics as defined in 
the sample QC.  
— Gender:  Genetic sex (Figure S5). 
— Supplementary reads / fraction of soft-clipped bases:  Fraction of reads with 
supplementary alignments, and fraction of mapped bases that are soft-clipped. 
— Pre-adapter/Bait oxo-G error pattern: Phred-scaled error indicating the presence of 
an oxoG error pattern. ‘Pre-adapter’ indicates oxoG errors that occurred before 
adapter ligation, such that read 1 carries G->T mutations and read 2 carries C->A 
mutations, while ‘Bait’ indicates an oxoG pattern which is exome bait-specific.  
— Presence of illumina adapters or poly-A tails: Fraction of reads with respectively 
Illumina adapters or poly-A tails.  
Non-technical covariates 
— PCA covariates: The top 10 PCA covariates, calculated after sample QC, using an 
approach described previously32. 
— Age: sample age (controls) or age-at-onset (cases). Missing values are imputed to 
the mean age.  
— AD status: case or control status 
— Haploblock markers: to obtain haploblock markers, we select nearby high-quality 
variants (passing variant QC, with minor allele frequency > 0.025% and a missingness 
< 10% (missingness defined as read depth < 6)). These variants were phased using 
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Eagle v2.439, with default settings. The resulting haploid genotype calls were used as 
covariates (algorithm detailed below). The region from which these ‘nearby’ variants 
are obtained was by default the 50kb up- and downstream from the variant that was 
tested for batch effects, with the exception of variants that were within 100bp (as there 
might be complex false positive events that present as multiple variants close 
together, which could present a false in-linkage signal). The region can be extended 
from 50kb up to a maximum of 250kb if there are too few variants (<25), or it can be 
reduced in size if too many are found (>1000).  
— Complex haploblock markers: In addition, a search is performed for combination of 
these nearby variants to better mark the haploblock(s) in which the tested variant 
occurs (detailed below). Allowed Boolean operations are AND and NOT (e.g. a 
covariate can be defined which is true if variant 1 AND NOT variant 2 are present in a 
sample).  
Forward-backward covariate search 
The above covariates are used in a regression model (detailed below) to explain the 
tested variant. Covariates are selected using a greedy forward selection/backward 
elimination approach. First, all covariates are normalized to a range 0-1. A covariate set 
E is defined, which contains covariates that are excluded from the regression, that is, their 
regression parameter is clamped to 0. Furthermore, a covariate set I is defined, which 
contains covariates that are part of the regression: the parameters of these covariates 
are optimized using a maximum-likelihood approach. Initially, all covariates are in set E, 
and the regression model is fitted using only an intercept.  
For all covariates in set E, the maximum likelihood gradient is determined. The covariate 
with the maximum gradient value is selected, and added to set I, after which the 
regression fit is reoptimized. If the AIC (Akaike Information Criterion40) score of the fit is 
improved, this step is accepted, and a new gradient search is performed to select the next 
covariate. If the AIC however decreases, the variant is removed from set I. The above 
steps are then repeated for the covariate with the next highest likelihood gradient. The 
forward search is stopped if none of the top 10 covariates improve the AIC metric. If more 
than 10 covariates are in set I, a backward elimination step is performed, in which each 
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covariate in set I is in turn dropped from the regression to determine if this improves the 
AIC score. This step is subsequently repeated every time when 5 new covariates have 
been added to set I.  
Prioritizing non-technical covariates 
To prioritize non-technical explanations for the presence of a variant, the above feature 
search is first performed using only non-technical covariates, until no model 
improvements can be found. The resulting AIC score is noted as the non-technical score. 
Next, technical covariates are added to the covariate set E, and the feature search is 
continued until no model improvements can be found anymore. The resulting score at 
that point is noted as the technical score. The final variant batch detection score is then 
calculated as the delta between these two scores, that is: vbd score = technical score - 
non-technical score.  
Diploid logistic regression model 
For haploid genotypes (chromosome Y), the above algorithm can be performed using a 
logistic regression model, in which 𝛾𝑗 = 𝑙𝑟(𝛼 + 𝛽𝑥𝑗) Here, j is the sample, lr is the logistic 
function, 𝛼 is the intercept, 𝑥𝑗 is the covariate vector for sample j, and 𝛽 is the vector with 
covariate regression parameters. Normally, in a standard logistic regression,  𝛾𝑗 ∈ {0,1}. 
However, due to low coverage data, 𝛾 is adapted to represent for each sample the 
probability of the alternate genotype being present (note: not the posterior probability, but 
the probability given by the variant caller).  Standard implementations of logistic 
regression usually perform a simplification of the maximum likelihood which assumes 
dichotomous labels. Therefore, a slightly more generic version of logistic regression was 
implemented which does not make this assumption. Let 𝑝𝑗(𝑎, 𝛽) = 𝑙𝑟(𝑎 + 𝛽𝑥𝑗). The log-
likelihood then takes the following form: 𝐿𝐿(𝑎, 𝛽)  =  ∑ 𝑙𝑜𝑔(𝛾𝑗  𝑝𝑗(𝑎, 𝛽)
 
𝑗 + (𝟏 − 𝜸𝒋)(𝟏 −
𝒑𝒋(𝒂, 𝜷))) −  𝝀 ∑ 𝜷𝒊
𝟐 
𝒊 . This function is maximized in terms of 𝑎 and 𝛽. A small 
regularization term 𝜆 = 0.005 is added to prevent problems with singularities. 
In case of diploid genotypes, this model does not suffice, as each sample can have either 
a reference, heterozygous or homozygous alternate genotype. The approach is to model 
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this as what can be seen as two coupled logistic regression models. Conceptually, in a 
simplified sense:  𝑑𝑗 = 𝑙𝑟(𝛼 + 𝛽𝑔𝑗,1 + 𝜃𝑥𝑗) + 𝑙𝑟(𝛼 + 𝛽𝑔𝑗,2 + 𝜃𝑥𝑗),  where 𝒅𝒋is a dosage for 
sample j, in the range [0,2], Here, gj,i is the matrix containing covariates that represent 
(complex combinations of) phased variants of sample j for haplotype i, and xj is the vector 
with covariate values for sample j that are haplotype-independent, with vector 𝜃 
containing the associated parameter values. Note that the two models share all 
parameters, but can differ (for phased variants) in their covariates.  
More in detail, this is not modelled through dosages, but through genotype probabilities 
rj, hj and oj, containing respectively the (non-posterior) genotype probabilities of the 
reference, heterozygous and homozygous alternate genotypes for sample j.  
Let 𝑝𝑗,𝑖(𝛼, 𝛽, 𝜃) = 𝑙𝑟(𝛼 + 𝛽𝑔𝑗,𝑖 + 𝜃𝑥𝑗), which will be noted more shortly as 𝑝𝑗,𝑖, then the 
maximum likelihood formulation takes the following form:  
𝐿𝐿(𝑎, 𝛽, 𝜃)  =  ∑ 𝑙𝑜𝑔(𝑟𝑗 (1 − 𝑝𝑗,1)(1 − 𝑝𝑗,2) + 𝒉𝒋(𝑝𝑗,1(1 − 𝑝𝑗,2)  +  (1 − 𝑝𝑗,1) 𝑝𝑗,2)  +
 
𝑗
 𝒐𝒋𝑝𝑗,1𝑝𝑗,2) −  𝝀(∑ 𝜷𝒌
𝟐 
𝒌 + ∑ 𝜽𝒍
𝟐 
𝒍 )  
To optimize this likelihood (as well as for the logistic regression model above), gradients 
were derived, and the optimization was implemented using the SLSQP optimizer 
available through Scipy41. 
Tree search for complex haploblock-markers 
Earlier, a forward selection-backward elimination algorithm was described to optimize the 
set of covariates. The main reason to use such an algorithm is clarified here. To tag a 
haploblock uniquely, the status of multiple SNPs is usually required to define an accurate 
marker (e.g. the marker is true if variant 1 is present, but not variant 2). Such markers are 
needed to define the haploblock(s) in which a tested variant occurs. Adding all possible 
combination of nearby variants would computationally be prohibitively expensive. Regular 
variant imputation algorithms have a similar problem, and solve this by using Hidden 
Markov Models on top of phased population haplotypes. It is however not immediately 
apparent how such an approach can be combined with a regular covariate regression 
framework as described above. Instead, to still enable the multi-variant haploblock 
markers, the forward-backward search is used to explore a tree of increasingly complex 
multi-variant haploblock markers.  
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The algorithm starts as described, with a set E of all covariates that are inactive, i.e. not 
part of the regression, and an empty set I which will contain all covariates that become 
‘active’, i.e. that are selected to be part of the regression model. Next to the covariates 
that do not represent a genetic variant, set E contains at the start only single-variant 
haplotype markers and no complex multi-variant haplotype markers. That is, the 
haplotype marker set 𝑄 ⊆ 𝐸is equal to M, where M is the set of single-variant markers 
that are near the  tested variant (see section on ‘non-technical covariates’ for how this set 
of markers is selected).  Once a marker 𝑞 ∈ 𝑄   is moved to set I,  we extend set Q (and 
thereby set E). For a positive association of q with the tested variant, we perform: 𝑄 =
𝑄 ∪ {𝑞 ∧ 𝑚, 𝑞 ∧ ¬𝑚|𝑚 ∈ 𝑀}, while for a negative association of q we perform:𝑄 = 𝑄 ∪
{¬𝑞 ∧ 𝑚, ¬𝑞 ∧ ¬𝑚|𝑚 ∈ 𝑀}. Upon removal of marker q from set I, the reverse operation is 
performed.  Note that usually in this case, one of the complex markers directly dependent 
on q has already been added to set I.  
Detection of missing-not-at-random genotypes 
While missing genotype calls are usually only observed due to lack of read coverage, this 
is not always the case. In certain situations, missingness was found to correlate with 
genotype status in certain batches (e.g. non-reference calls were more likely to be 
missing). This is not detected through the above algorithm, as for a missing genotype call 
all possible genotypes have the same probability, and therefore the sample has, as 
designed,  no effect on the likelihood of the regression model. To detect these situations, 
the regression model optimized with the non-technical covariates (first step of algorithm) 
was used to impute the dosage of all samples.  Then, a Fisher exact test was performed 
for each batch and contributing study,  to detect possible allele frequency  differences 
between samples for which the genotype call is missing, and for samples for which the 
genotype is not missing. More in detail, an imputed posterior dosage is determined using 
the maximum likelihood fit of the ‘non-technical’ regression model: 𝑑𝑗   =  𝑝𝑗,1(1 − 𝑝𝑗,2)  +
 (1 − 𝑝𝑗,1) 𝑝𝑗,2  + 𝟐𝑝𝑗,1𝑝𝑗,2. Next, an allele-based Fisher exact test (number of alleles is 2 
times number of samples) is performed for each batch and study separately, contrasting 
samples with a missing genotype call with samples with a non-missing genotype call. P-
values < 1e-6 are considered indicative of a problematic  batch effect.  
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Two-phase approach 
In some cases, variants that were used as haploblock markers  themselves carried large 
batch effects. Due to this, nearby variants with a similar batch effect pattern were not 
detected as having such a batch effect. To prevent this from occurring, a two-phase 
approach was adopted. In the first phase, VBD was run without any haploblock markers. 
This meant that the non-technical regression model only used the PCA and phenotype 
covariates. This results in a conservative scoring, as less of the variant is explained by 
non-technical covariates. Variants that scored a VBD score > 25 in this phase were 
excluded as haploblock marker in the second phase. In the second phase, the algorithm 
was then performed as described above, but without the haploblock markers that were 
excluded by the first phase.  
Variant batch correction 
For many variants, problematic technical effects were limited to certain batches. In such 
cases, exclusion of the whole variant seemed unwarranted. To correct these variants, we 
performed a batch correction step. Variants with a VBD score > 25, or a VBD score > 15 
and a MAF < 0.05%, or a batch with a missing genotype batch p-value < 1e-6 were 
considered for correction. The correction process was performed iteratively, and 
continued until the VBD score < 10, and the minimum missing genotype batch p-value > 
1e-4, or if the variant could not be corrected further. In each iteration, correction was 
performed in two steps. First, the correction process walked through the technical 
covariates in order of their addition to the regression model. If such a technical covariate 
described a batch, study or capture kit and led to an AIC score jump of at least 5, the 
genotypes for the variant under consideration were set to missing for all samples of such 
a batch, study or capture kit. This process was stopped once a covariate was encountered 
that did not fall under these criteria. Second, the correction process walked through all 
batches with a missing genotype batch p-value <1e-4, which were set to missing as well. 
If no batches had a p-value <1e-4, but there were contributing studies with a missing 
genotype p-value <1e-4, then studies were considered instead. Variant were annotated 
both with VBD results before and after correction.  
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Variant filtering 
Finally, variants were considered for analysis if after correction they had a VBD score < 
25, or a VBD score < 15 if they had a MAF < 0.05%.  
 
Variant selection and annotation 
For the association tests, we performed variant selection (Figure 1c).  
1. Protein coding transcripts.  
We selected variants in autosomal protein-coding genes that were annotated by VEP 
(version 94.542)to affect the Ensembl basic set of protein coding transcripts (Gencode 
v19/v29 (liftover to build 37)43) of these genes. Transcripts of both Gencode versions were 
merged based on their identifier, with preference given to the v29-based annotation. 
Transcripts that passed our filter (protein coding + basic tag) in v19 but not in v29 were 
not considered.  
2. Variant type. 
We only kept variants that directly affected the protein (missense, stop_gained, 
splice_acceptor, splice_donor or frameshift annotation). For LOF annotations, we only 
kept those variants with a ‘HIGH’ VEP impact classification, while for missense 
annotations we required a ‘MODERATE’ VEP impact classification.  
3. Variant prioritization.  
We prioritized missense variants using REVEL (Rare Exome Variant Ensemble 
Learner)44 (annotation obtained from DBNSFP4.0a45 and only kept variants with a score 
≥ 25 (score range 0 - 100). LOF variants were prioritized using LOFTEE28 (version 1.0.2), 
and only LOF variants that had a LOFTEE ‘high-confidence’ flag were kept.  
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4. Variant frequency.  
Of these, we only kept variants that were estimated to have at least one carrier, and had 
a minor allele frequency (MAF) of <1%.  
5. Variant missingness.  
Finally, we removed (5) variants with >20% genotyping missingness (genotypes with a 
read depth < 6 are considered missing), or that did not pass a filter for differential 
missingness between the EOAD, LOAD and control groups (Fisher-Exact test comparing 
EOAD cases versus controls and LOAD cases versus controls, p<1e-20).  
6. Variant categorization.  
Variants were divided in 4 deleteriousness categories: a LOF category, and 3 missense 
categories: REVEL ≥ 75, REVEL 50-75 and REVEL 25-50 (Figure 1c).  
Analyses and statistical tests 
Gene burden test 
Based on previous findings in SORL1, TREM2 and ABCA75 an enrichment can be expected of 
high impact rare risk variants in early onset cases compared to late onset cases. A regular 
case/control test (in which only a subset of the cases is EOAD) would be inefficient in picking up 
such signals. The alternative, performing an additional test that specifically tests for burden in 
EOAD cases, would however also be inefficient as (1) the additional signal from the LOAD cases 
would be excluded from the analysis and (2) adding such a test would lead to additional correction 
for multiple testing. Therefore, we combined both case-control and EOAD tests into one, through 
the use of ordinal logistic regression, where the genetic risk for AD is considered to increase 
EOAD > LOAD > control. This test is optimally suited for picking up differential variant loads 
between the sample categories (EOAD > LOAD > Control), but it can also pick up regular case-
control signals for which genetic risk is equally distributed across EOAD and LOAD cases (EOAD 
~ LOAD > Control) as well as EOAD-specific signals (EOAD > LOAD ~ Control). The burden 
test was implemented with the ordinal regression implementation available in the MASS 
package (version 7.3-51.5) for R (version 3.4.3). Six PCA population covariates 
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(calculated on the samples remaining after sample QC, using an approach described 
previously32 were used, Figure S16, Figure S17, Figure S18), and p-values were 
calculated using a likelihood ratio test (‘lrtest’ function from the lmtest package, version 
0.9-35). An additive model was considered, by summing the dosages of the minor alleles 
of selected variants. To prevent biases due to missing or low coverage, we sampled the 
dosage of each variant call (i.e. 0,1 or 2) according to the posterior probabilities (see 
above) of the reference, heterozygous or homozygous genotypes. The burden test was 
performed multiple times with independently sampled dosages, to account for sampling 
uncertainty. P-values and beta values were averaged across these runs, while standard 
deviations were first converted to variances and then averaged. Repeated runs were 
performed until either the standard deviation of the mean of log10 transformed p-values 
became < 0.01, 100 runs were reached, or a mean p-value > 0.01 was obtained with at 
least 25 runs, or a mean p-value > 0.1 with at least 5 runs.  
Variant impact thresholds  
We tested the evidence for a differential burden for four sets of variants with incrementing 
levels of predicted deleteriousness: the LOF+REVEL≥25 threshold includes the variants 
from all deleteriousness categories, while the LOF+REVEL≥50 threshold and 
LOF+REVEL≥75 threshold condition on the variants with higher levels of predicted 
deleteriousness. Finally, the LOF threshold includes only variants that are predicted to 
lead to a complete loss-of-function. The rationale behind this is that for each gene, by 
concentrating maximum evidence for a differential burden-signal in one test, we maximize 
the power to identify a differential burden in this gene. Genes were only tested if the 
cumulative minor allele count (cMAC) of predicted damaging variants was ≥10. Multiple 
testing correction was performed across all performed tests (up to 4 per gene) using the 
False Discovery Rate procedure46. Genes were considered for replication if the false 
discovery rate was ≤20%. Additionally, we used family-wise correction using the Holm-
Bonferoni procedure47 to select genes that were significant in our discovery sample 
(corrected p < 0.05).  
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Carrier frequency and cumulative Minor Allele Frequency 
A carrier of a set of variants was defined as a sample for which the summed dosage of 
those variants was ≥0.5. Carrier frequencies (CFs) were determined as #carriers / 
#samples. Confidence intervals for the CFs were assumed to be described through a 
Beta distribution (where a=#carriers, and b=#samples - #carriers). To accommodate 
situations for certain age-at-onset bins, in which the number of carriers was (close to) 0, 
a prior was added to a and b based on the carrier count in samples not included in the 
age-at-onset bin, scaled such that a=0.1. The cumulative Minor Allele Frequency (cMAF) 
for a set of variants and samples was defined as the sum of the minor allele frequencies 
(MAFs) of the included variants in those samples. When the summed frequency of these 
variants is <1%, the cMAF can be considered to have a similar uncertainty distribution as 
the MAF, which can be described using a Beta distribution, where a=#cumulative Minor 
Allele Count (cMAC) and b=2 * #samples - cMAC. Similar as for the CF, a prior was added 
based on the observed allele counts in non-included samples, scaled such that a=0.1.  
Odds ratios 
Effect sizes (odds ratios, ORs) of the ordinal logistic regression can be interpreted as 
weighted averages of the OR of being an AD case versus control, and the OR of being 
an early-onset AD case or not. Ordinal odds ratios were calculated for each test, as well 
as separately for the 4 variant categories REVEL 25-50, 50-75, 75-100 and LOF. Next to 
ordinal ORs, we estimated ‘standard’ ORs. This was done across all samples 
(case/control), as well as per age category (EOAD versus controls and LOAD versus 
controls), as well as for smaller age-at-onset categories: ≤65 (EOAD), (65-70], (70-80] 
and >80. Standard ORs were estimated using multinomial logistic regression, using the 
R nnet package (version 7.3-12), with correction for 6 PCA covariates. For low cMAC 
values, logistic regression has difficulties in obtaining accurate odds ratios and confidence 
intervals, as the normal distribution approximation for the log(OR) parameter starts to 
break down. For these situations (where cMAC≤10, or <3 for either cases or controls), the 
OR and its confidence intervals were estimated directly based on the cMAF of cases and 
controls: OR = (cMAFcase / cMAFcontrol) / ((1 - cMAFcase) / (1 - cMAFcontrol). While the 
uncertainty of this OR is difficult to evaluate directly, it is governed by the uncertainty in 
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cMAFcase and cMAFcontrol. Confidence intervals were therefore estimated through the 
earlier described beta distribution approximation for the cMAF, by repeated sampling of 
possible cMAFcase and cMAFcontrol values.  
Testing for an age-at-onset or a deleteriousness-category effect 
We tested if enrichments of damaging variants increased (or decreased for protective 
variants) towards younger patients. To this end, an ordinal regression using only cases 
(no controls) was performed, in which cases were grouped in 4 age-at-onset bins: ≤65 , 
(65-70], (70-80] and <80+. A significant effect (FDR < 0.05) signaled that there was a 
difference in enrichment between young and older cases. To determine if there was a 
significant difference in effect sizes between the different deleteriousness categories 
(REVEL 25-50, 50-75, 75-100 and LOF), an ordinal logistic regression test was performed 
in which the H0 model included a single beta parameter for all deleteriousness categories, 
while the H1 model included 4 separate betas for the 4 deleteriousness categories (or <4 
when missense deleteriousness categories with cMAC <5 were merged, see caption of 
Figure 4 for details). We tested if there was a trend effect, in which effect sizes increased 
with increasing predicted damagingness (REVEL 25-50 < REVEL 50-75 < REVEL 75-
100 < LOF). To this end, we modified the ordinal logistic regression implementation, by 
adding a constraint on the beta parameters: |𝑏𝑅𝐸𝑉𝐸𝐿 25−50| ≤ |𝑏𝑅𝐸𝑉𝐸𝐿 50−75| ≤
|𝑏𝑅𝐸𝑉𝐸𝐿 75−100| ≤ |𝑏𝐿𝑂𝐹| (or equivalent for genes where variant categories were merged). 
Subsequently, optimization was performed by first estimating b in an unconstrained 
model, followed by adding the model constraints. Likelihood-ratios in this setting follow a 
chi-bar-squared distribution. Significance (FDR < 0.05) was therefore determined through 
sample label permutation, based on the bootstrapping approach outlined in Garre et al 48. 
The number of permutations was limited to 10.000.  
Sensitivity analysis 
A sensitivity analysis was performed to determine if effects were potentially due to age 
differences between cases and controls (Figure S2). An age-matched sample was 
constructed by dividing samples in strata based on age/age-at-onset, with each stratum 
covering 2.5 years. Case/control ratios in all strata were kept between 0.1 and 10 by 
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down-sampling respectively controls or cases. Subsequently, samples were weighted 
using the propensity weighting within strata method proposed by Posner and Ash49. 
Finally, a case-control logistic regression was performed both on the unweighted and 
weighted case-control labels, and estimated odds ratios and confidence intervals were 
compared.  
Variant-specific analysis 
We performed a variant-specific analysis of the genes considered as significantly or 
suggestively associated with AD, to detect gene-specific idiosyncrasies not covered by 
our uniform exome-wide analysis. We checked for outlier variants among those that were 
included in the burden test, determining which ones had a significantly lower or opposite 
effect size (fisher exact test) compared to other included variants of the same category 
(missense or LOF). Furthermore, we determined which missense or potential LOF 
variants did associate with AD (logistic regression test, at least 15 carriers), irrespective 
of REVEL/LOFTEE or MAF thresholds. We performed corrections for multiple testing per 
gene using FDR, reporting only variants with a threshold of FDR < 0.2 (Table S3). We 
manually removed and added these variants to the burden tests, in order to calculate, 
next to standard odds ratios, also refined odds ratios. 
Detailed gene discussion 
Results of the variant-specific analysis can be found in Table S3. For each gene, we 
discuss 1) variants that were included in the burden test, but found to be outliers, 2) 
missense and potential LOF variants that associated with AD, 3) other variants of interest. 
SORL1 
We detected two variants that associated with AD: i) A528T (OR 1.16, 95% CI: 1.05-1.27, 
MAF 4.9%, FDR: 4%), a common variant, which therefore was not added to the (refined) 
burden test, ii) a suggestive association for the rare V1459I variant (OR 2.5, 95% CI: 1.22-
5.07, FDR: 20%), which due to its REVEL score was not included in the burden test, but 
was added to the refined analysis. One missense SORL1 variant (S2175R) was detected 
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as outlier (FDR 6.3%) to the burden test, as it had OR of 0.53 (95% CI 0.19-1.47), lower 
than other missense variants.  This variant was removed from the burden test in the 
refined analysis. The addition of V1459I and removal of S2175R in the refined burden 
analysis changed the SORL1 missense OR from 2.2 to 2.5 (Table 1). 
TREM2 
We detected 5 missense variants that associated with AD: i) R47H50 (OR 3.7, 95%CI 2.8-
4.9, FDR: 3.8e-10%), which was included in the burden test, ii) R62H51 (OR 1.6, 95%CI 
1.3-1.9, MAF 1.3%, FDR: 0.0006%), which is common, and was therefore not included in 
the (refined) burden test, iii) a new significant association for D87N (OR 2.6, 95%CI, 1.6-
4.6, MAF:0.15%, FDR: 1%), iv) we confirmed the recently significantly associated 
H157Y50 (OR 6.4, 95%CI: 2.7-15.2, MAF:0.05%, FDR:1%), and v) found a new significant 
association in L211P (OR 2.3, 95%CI: 1.3-3.9, MAF:0.05%, FDR:2%). The last three 
variants all had a low REVEL score, and were therefore not included in the burden test, 
but were added to the refined analysis. Notably, missense variant L211P affects only the 
canonical transcript, while the other mentioned missense variants affect all 3 protein-
coding transcripts of TREM2. For LOF variants, we detected an outlier splice acceptor 
variant rs538447052 (OR: 1.9, 95%CI: 0.7-5.1, MAF: 0.04%), which only affected the non-
canonical ENST00000373122 transcript. This variant had a significantly lower odds ratio 
(outlier FDR: 11%)  compared to the other LOF variants that affect all transcripts. It was 
therefore removed in the refined analysis. Furthermore, we also note a suggestive 
association for a stop gained variant which only affected the soluble TREM2 transcript 
ENST00000338469 (OR: 2.3, 95%CI: 0.9-5.8, FDR: 20%). This variant was carried by 20 
individuals (17 cases, 3 controls), and was not included in our burden test as it had a low-
confidence classification from LOFTEE due to its location in the last exon. Given the 
different biological effect and the relatively lower OR compared to the other LOF variants 
that affect all transcripts, this variant was not added to the refined analysis.  After 
refinement (inclusion of D87N, H157Y, L211P, and removal of the splice acceptor LOF 
variant for the non-canonical transcript), the LOF odds ratio of TREM2 was determined 
to be 10.8 (95% CI: 4.4-26.9), while the missense OR 3.5 (95% CI:3.1-6.1).  
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ABCA7 
We associated 4 missense variants in ABCA7: i) L101R (OR: 3.7, 95%CI 2.1-6.4, FDR: 
0.5%), which was included in the burden test, ii) a new significant association for a 
common protective variant G215S (OR: 0.89, 95%CI: 0.81-0.97, FDR: 2%), for which 
previously a suggestive protective association was found52, iii and iv) a protective 
association in common variants H395R and Q1686R, which are (known to be) in tight 
linkage 53. For H395R, a damaging association was previously found in African 
Americans54, where the variant is much more common (25% vs. 3.5% in our study). These 
4 variants did not lead to any changes in the refined burden analysis. Additionally, there 
were 2 missense variants detected as outlier in the burden test: i) R19W (outlier FDR: 
5%), with an OR of 1.09 (95% CI: 0.4-3.2). We note that the OR in our study might be 
underestimated, as this variant was mainly present in young controls (median age 57). ii) 
V1599M (outlier FDR:1.8%), with an OR of 0.84 (95%CI: 0.61-1.15, MAF:0.4%). In the 
refinement analysis, these two variants were removed.  The resulting missense OR in the 
burden test was 1.4 (95%CI: 1.3-1.6).  Of note, our discovery analysis excluded two 
relatively often occurring LOF variants, flagged in our QC pipeline for differential 
missingness. However, for these variants, it was possible to reliably calculate a single-
variant association (by excluding samples with low depth). The first variant is the splice-
altering variant c.5570+5G>C, which maps outside the closest canonical splice site and 
hence did not fulfill our inclusion criteria for the exome wide burden tests. A loss of 
function effect was demonstrated in vitro for this variant1. In our study, we observed an 
OR of 1.67 (95%CI 1.2-2.3, p=0.002, MAF=0.43%). The second variant is the LOF 
frameshift variant 708-710:EEQ/X (earlier observed by de Roeck et al55) for which we 
report an OR of 2.0 (95%CI 1.36-3.01, p=0.003, MAF=0.27%).  These odds ratios are in 
line with those obtained for the LOF burden test (OR 1.8, 95%CI: 1.2-2.6). Finally, we did 
not have the possibility to call an intronic variable number tandem repeat (VNTR) which 
was recently associated with an increased risk of developing AD, suggesting that the level 
of association of ABCA7 in AD is still likely underestimated in our study56. However, it is 
important to keep in mind that the real impact of some LOF mutations in ABCA7 may be 
restricted by a transcript rescue mechanism55. 
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ABCA1 
We associated 5 missense variants in ABCA1 with AD: i,ii) two common missense 
variants V825I and I883M, with a (suggestive) protective association with AD: OR 0.93  
and OR 0.91 respectively. iii)  A rare suggestive protective association of variant A1182T 
(OR 0.49, 95%CI: 0.25-0.95, FDR: 13%). iv) A rare suggestive association with increased 
AD risk of variant R1680Q (OR 2.75, 95% CI: 1.27-5.95, FDR: 13%). v) A significant 
association with 4.2-fold increased AD risk of variant N1800H (OR 4.2; 95%CI: 2.0-8.6, 
FDR:2%, MAF: 0.08%).  This variant was not included in our burden test due to a low 
REVEL core. Furthermore, we detected 2 variants as outlier in the burden test: vi) a 
missense variant (outlier FDR: 4.8%) in D1018G (OR 0.81, 95%CI: 0.29-2.22, 
MAF:0.04%) and vii) a splice donor variant (outlier FDR: 0.3%, 9:107565564:C>A), which 
had an OR of 0.94 (95%CI: 0.19-4.52, MAF: 0.02%). In our refinement analysis, we 
removed the latter variants (vi and vii) and added variants (iv) R1680Q and (v) N1800H. 
The burden of all LOF associated with a 5-fold increased risk for AD (OR 4.9, 95%CI 2.1-
11.4) and the burden of all missense mutations associated with a 2-fold increased risk of 
AD (OR 2.1, 95%CI: 1.6-2.7).  
ADAM10 
We note that one splice-acceptor LOF variant, carried by a single control, only affects 
transcripts ENST00000402627 and ENST00000561288. These transcripts, being 71 and 
38 amino acids long, miss the majority of the canonical transcript (748 amino acids). This 
individual was last checked at age 89.  
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Disease controls (NS039764, NS071674, 5RC2HG005605), University of Miami (R01 
AG027944, R01 AG028786, R01 AG019085, IIRG09133827, A2011048), the Multi-
Institutional Research in Alzheimer’s Genetic Epidemiology Study (MIRAGE) (R01 
AG09029, R01 AG025259), the National Cell Repository for Alzheimer’s Disease 
(NCRAD) (U24 AG21886), the National Institute on Aging Late Onset Alzheimer's 
Disease Family Study (NIA- LOAD) (R01 AG041797), the Religious Orders Study (ROS) 
(P30 AG10161, R01 AG15819), the Texas Alzheimer’s Research and Care Consortium 
(TARCC) (funded by the Darrell K Royal Texas Alzheimer's Initiative), Vanderbilt 
University/Case Western Reserve University (VAN/CWRU) (R01 AG019757, R01 
AG021547, R01 AG027944, R01 AG028786, P01 NS026630, and Alzheimer’s 
Association), the Washington Heights-Inwood Columbia Aging Project (WHICAP) (RF1 
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AG054023), the University of Washington Families (VA Research Merit Grant, NIA: 
P50AG005136, R01AG041797, NINDS: R01NS069719), the Columbia University 
HispanicEstudio Familiar de Influencia Genetica de Alzheimer (EFIGA) (RF1 AG015473), 
the University of Toronto (UT) (funded by Wellcome Trust, Medical Research Council, 
Canadian Institutes of Health Research), and Genetic Differences (GD) (R01 AG007584). 
The CHARGE cohorts are supported in part by National Heart, Lung, and Blood Institute 
(NHLBI) infrastructure grant HL105756 (Psaty), RC2HL102419 (Boerwinkle) and the 
neurology working group is supported by the National Institute on Aging (NIA) R01 grant 
AG033193. R01 AG048927 for the Gwangju Alzheimer and Related Dementias Study,  
RF1 AG054080 to Dr. Beechem, U24 AG056270 to Dr. Mayeux, RF1 AG057519  to Dr. 
Farrer and Pericak-Vance, U01 AG062602 to Dr. Farrer, R01 AG067501 to Dr. Mayeux, 
and P30 AG13846 to Dr. Farrer 
The CHARGE cohorts participating in the ADSP include the following: Austrian Stroke 
Prevention Study (ASPS), ASPS-Family study, and the Prospective Dementia Registry-
Austria (ASPS/PRODEM-Aus), the Atherosclerosis Risk in Communities (ARIC) Study, 
the Cardiovascular Health Study (CHS), the Erasmus Rucphen Family Study (ERF), the 
Framingham Heart Study (FHS), and the Rotterdam Study (RS). ASPS is funded by the 
Austrian Science Fond (FWF) grant number P20545-P05 and P13180 and the Medical 
University of Graz. The ASPS-Fam is funded by the Austrian Science Fund (FWF) project 
I904),the EU Joint Programme - Neurodegenerative Disease Research (JPND) in frame 
of the BRIDGET project (Austria, Ministry of Science) and the Medical University of Graz 
and the Steiermärkische Krankenanstalten Gesellschaft. PRODEM-Austria is supported 
by the Austrian Research Promotion agency (FFG) (Project No. 827462) and by the 
Austrian National Bank (Anniversary Fund, project 15435. ARIC research is carried out 
as a collaborative study supported by NHLBI contracts (HHSN268201100005C, 
HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, 
HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and 
HHSN268201100012C). Neurocognitive data in ARIC is collected by U01 
2U01HL096812, 2U01HL096814, 2U01HL096899, 2U01HL096902, 2U01HL096917 
from the NIH (NHLBI, NINDS, NIA and NIDCD), and with previous brain MRI 
examinations funded by R01-HL70825 from the NHLBI. CHS research was supported by 
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contracts HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, 
N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, and grants 
U01HL080295 and U01HL130114 from the NHLBI with additional contribution from the 
National Institute of Neurological Disorders and Stroke (NINDS). Additional support was 
provided by R01AG023629, R01AG15928, and R01AG20098 from the NIA. FHS 
research is supported by NHLBI contracts N01-HC-25195 and HHSN268201500001I. 
This study was also supported by additional grants from the NIA (R01s AG054076, 
AG049607 and AG033040 and NINDS (R01 NS017950). The ERF study as a part of 
EUROSPAN (European Special Populations Research Network) was supported by 
European Commission FP6 STRP grant number 018947 (LSHG-CT-2006-01947) and 
also received funding from the European Community's Seventh Framework Programme 
(FP7/2007-2013)/grant agreement HEALTH-F4- 2007-201413 by the European 
Commission under the programme "Quality of Life and Management of the Living 
Resources" of 5th Framework Programme (no. QLG2-CT-2002- 01254). High-throughput 
analysis of the ERF data was supported by a joint grant from the Netherlands 
Organization for Scientific Research and the Russian Foundation for Basic Research 
(NWO-RFBR 047.017.043). The Rotterdam Study is funded by Erasmus Medical Center 
and Erasmus University, Rotterdam, the Netherlands Organization for Health Research 
and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the 
Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, 
the European Commission (DG XII), and the municipality of Rotterdam. Genetic data sets 
are also supported by the Netherlands Organization of Scientific Research NWO 
Investments (175.010.2005.011, 911-03-012), the Genetic Laboratory of the Department 
of Internal Medicine, Erasmus MC, the Research Institute for Diseases in the Elderly (014-
93-015; RIDE2), and the Netherlands Genomics Initiative (NGI)/Netherlands 
Organization for Scientific Research (NWO) Netherlands Consortium for Healthy Aging 
(NCHA), project 050-060-810. All studies are grateful to their participants, faculty and 
staff. The content of these manuscripts is solely the responsibility of the authors and does 
not necessarily represent the official views of the National Institutes of Health or the U.S. 
Department of Health and Human Services. 
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The four LSACs are: the Human Genome Sequencing Center at the Baylor College of 
Medicine (U54 HG003273), the Broad Institute Genome Center (U54HG003067), The 
American Genome Center at the Uniformed Services University of the Health Sciences 
(U01AG057659), and the Washington University Genome Institute (U54HG003079). 
  
Biological samples and associated phenotypic data used in primary data analyses were 
stored at Study Investigators institutions, and at the National Cell Repository for 
Alzheimer’s Disease (NCRAD, U24AG021886) at Indiana University funded by NIA. 
Associated Phenotypic Data used in primary and secondary data analyses were provided 
by Study Investigators, the NIA funded Alzheimer’s Disease Centers (ADCs), and the 
National Alzheimer’s Coordinating Center (NACC, U01AG016976) and the National 
Institute on Aging Genetics of Alzheimer’s Disease Data Storage Site (NIAGADS, 
U24AG041689) at the University of Pennsylvania, funded by NIA This research was 
supported in part by the Intramural Research Program of the National Institutes of health, 
National Library of Medicine. Contributors to the Genetic Analysis Data included Study 
Investigators on projects that were individually funded by NIA, and other NIH institutes, 
and by private U.S. organizations, or foreign governmental or nongovernmental 
organizations. 
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